Publications by Sverre Erik Kjeldsen
754 publications found
Original articles
Medical Measures in Hypertensives Considered Resistant
Am J Hypertens, 37 (5), 307-317
DOI 10.1093/ajh/hpad118, PubMed 38124494
What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence
Am J Hypertens, 37 (1), 1-14
DOI 10.1093/ajh/hpad073, PubMed 37551929
Effect of antihypertensive treatment in isolated systolic hypertension (ISH) - systematic review and meta-analysis of randomised controlled trials
Blood Press, 32 (1), 2226757
DOI 10.1080/08037051.2023.2226757, PubMed 37395100
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)
J Hypertens, 41 (12), 1874-2071
DOI 10.1097/HJH.0000000000003480, PubMed 37345492
Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
Am J Hypertens, 36 (10), 536-541
DOI 10.1093/ajh/hpad057, PubMed 37382177
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg
Hypertension, 80 (8), 1739-1748
DOI 10.1161/HYPERTENSIONAHA.123.21454, PubMed 37350267
How to optimize the use of diuretics in patients with heart failure?
Kardiol Pol, 81 (10), 944-949
DOI 10.33963/v.kp.97315, PubMed 37718589
Renal denervation in the antihypertensive arsenal - knowns and known unknowns
J Hypertens, 40 (10), 1859-1875
DOI 10.1097/HJH.0000000000003171, PubMed 36052518
Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy
J Am Heart Assoc, 11 (18), e025879
DOI 10.1161/JAHA.121.025879, PubMed 36073648
Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study
Rev Cardiovasc Med, 23 (3), 95
DOI 10.31083/j.rcm2303095, PubMed 35345262
The Oslo Ischaemia Study: cohort profile
BMJ Open, 11 (10), e049111
DOI 10.1136/bmjopen-2021-049111, PubMed 34645662
Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure
J Hypertens, 39 (10), 2022-2029
DOI 10.1097/HJH.0000000000002894, PubMed 34102659
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
J Hypertens, 39 (8), 1522-1545
DOI 10.1097/HJH.0000000000002910, PubMed 34102660
Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations
Hypertension, 78 (3), 617-628
DOI 10.1161/HYPERTENSIONAHA.121.17514, PubMed 34275336
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
Lancet Oncol, 22 (4), 558-570
DOI 10.1016/S1470-2045(21)00033-4, PubMed 33794209
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk
Blood Press, 30 (2), 90-97
DOI 10.1080/08037051.2020.1856642, PubMed 33403890
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension
Blood Press, 30 (2), 82-89
DOI 10.1080/08037051.2020.1855968, PubMed 33403886
[Ten-year prediction of cardiovascular disease in healthy Norwegian men, based on NORRISK-2]
Tidsskr Nor Laegeforen, 140 (12)
DOI 10.4045/tidsskr.20.0089, PubMed 32900157
Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study
Blood Press, 30 (1), 51-59
DOI 10.1080/08037051.2020.1787815, PubMed 32633143
On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy
Blood Press, 29 (5), 319-326
DOI 10.1080/08037051.2020.1782171, PubMed 32586143
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients
Circulation, 142 (7), 621-642
DOI 10.1161/CIRCULATIONAHA.120.046361, PubMed 32546049
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers
Hypertension, 75 (6), 1584-1592
DOI 10.1161/HYPERTENSIONAHA.119.14443, PubMed 32336236
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies
Eur Heart J, 41 (16), 1588-1599
DOI 10.1093/eurheartj/ehaa121, PubMed 32211888
Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men
Stroke, 51 (5), 1435-1441
DOI 10.1161/STROKEAHA.119.027233, PubMed 32268850
Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men
Hypertension, 75 (1), 44-50
DOI 10.1161/HYPERTENSIONAHA.119.13528, PubMed 31735088
Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study
Blood Press, 28 (5), 317-326
DOI 10.1080/08037051.2019.1633905, PubMed 31259628
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up
J Hypertens, 37 (5), 949-955
DOI 10.1097/HJH.0000000000001959, PubMed 30325341
Heart Failure with normal ejection fraction
Tidsskr. Nor. Laegeforen., 139 (6), 522-527
Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients
J Hypertens, 37 (3), 629-635
DOI 10.1097/HJH.0000000000001915, PubMed 30676480
Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study
Blood Press, 28 (2), 84-92
DOI 10.1080/08037051.2019.1569463, PubMed 30698038
[2018 ESC/ESH Guidelines for the management of arterial hypertension]
Kardiol Pol, 77 (2), 71-159
DOI 10.5603/KP.2019.0018, PubMed 30816983
Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men
Stroke, 50 (1), 155-161
DOI 10.1161/STROKEAHA.118.021798, PubMed 30580727
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension
J Hypertens, 36 (12), 2284-2309
DOI 10.1097/HJH.0000000000001961, PubMed 30379783
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Blood Press, 27 (6), 314-340
DOI 10.1080/08037051.2018.1527177, PubMed 30380928
[2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]
G Ital Cardiol (Rome), 19 (11 Suppl 1), 3S-73S
DOI 10.1714/3026.30245, PubMed 30520455
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
J Hypertens, 36 (10), 1953-2041
DOI 10.1097/HJH.0000000000001940, PubMed 30234752
2018 ESC/ESH Guidelines for the management of arterial hypertension
Eur Heart J, 39 (33), 3021-3104
DOI 10.1093/eurheartj/ehy339, PubMed 30165516
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
Eur Heart J, 39 (24), 2243-2251
DOI 10.1093/eurheartj/ehx760, PubMed 29365085
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study
J Hypertens, 36 (4), 916-923
DOI 10.1097/HJH.0000000000001620, PubMed 29176391
Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future
Eur Heart J, 38 (44), 3272-3281
DOI 10.1093/eurheartj/ehx215, PubMed 28475773
From 'essential' hypertension to intensive blood pressure lowering: the pros and cons of lower target values
Eur Heart J, 38 (44), 3258-3271
DOI 10.1093/eurheartj/ehx643, PubMed 29177419
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension
J Am Heart Assoc, 6 (11)
DOI 10.1161/JAHA.117.007564, PubMed 29151037
[Not Available]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.17.0794, PubMed 29043734
Long-term predictors of stroke in healthy middle-aged men
Int J Stroke, 13 (3), 292-300
DOI 10.1177/1747493017730760, PubMed 28929941
New guidelines for the prevention of cardiovascular disease
Tidsskr. Nor. Laegeforen., 137 (16), 1164-1168
New guidelines for the prevention of cardiovascular disease
Tidsskr Nor Laegeforen, 137 (16)
DOI 10.4045/tidsskr.17.0109, PubMed 28871738
Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension
Blood Press, 26 (6), 321-331
DOI 10.1080/08037051.2017.1320939, PubMed 28489464
Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis
Blood Press, 26 (4), 195-203
DOI 10.1080/08037051.2017.1311769, PubMed 28443356
Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men
Blood Press, 26 (4), 229-236
DOI 10.1080/08037051.2017.1291276, PubMed 28276720
Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy Middle-Aged Men: a 28-Year Follow-Up Study
J Am Heart Assoc, 5 (12)
DOI 10.1161/JAHA.116.004555, PubMed 27881424
Impact of achieved systolic blood pressure on renal function in hypertensive patients
Eur Heart J Qual Care Clin Outcomes, 2 (4), 271-276
DOI 10.1093/ehjqcco/qcw017, PubMed 29474712
Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study
J Clin Pharm Ther, 41 (6), 695-702
DOI 10.1111/jcpt.12451, PubMed 27670639
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy
J Hypertens, 34 (9), 1831-7
DOI 10.1097/HJH.0000000000000989, PubMed 27254312
Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial
J Hum Hypertens, 31 (3), 178-188
DOI 10.1038/jhh.2016.54, PubMed 27511476
Relationship between abnormal P-wave terminal force in lead V1 and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study
Blood Press, 26 (2), 94-101
DOI 10.1080/08037051.2016.1215765, PubMed 27601135
Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy
Blood Press, 25 (6), 364-372
DOI 10.1080/08037051.2016.1179514, PubMed 27146272
Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension
J Hypertens, 34 (5), 813-21
DOI 10.1097/HJH.0000000000000865, PubMed 26982382
Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses
J Clin Pharmacol, 56 (9), 1120-9
DOI 10.1002/jcph.712, PubMed 26829251
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Clin Drug Investig, 36 (3), 225-33
DOI 10.1007/s40261-015-0372-9, PubMed 26718960
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial
Blood Press, 25 (4), 235-40
DOI 10.3109/08037051.2015.1134071, PubMed 26808585
Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes
Eur J Intern Med, 29, 26-31
DOI 10.1016/j.ejim.2015.11.027, PubMed 26712453
A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients
J Hypertens, 33 (12), 2534-45
DOI 10.1097/HJH.0000000000000749, PubMed 26485460
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy
J Hypertens, 33 (12), 2422-30
DOI 10.1097/HJH.0000000000000739, PubMed 26378687
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial
Blood Press, 25 (2), 83-92
DOI 10.3109/08037051.2015.1106750, PubMed 26511535
Family history of hypertension and serum triglycerides predict future insulin sensitivity: a 17-year follow-up study of young men
J Hypertens, 33 (9), 1845-51; discussion 1852
DOI 10.1097/HJH.0000000000000632, PubMed 26103130
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
J Hypertens, 33 (7), 1480-6
DOI 10.1097/HJH.0000000000000559, PubMed 25799208
Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients
Stroke, 46 (8), 2113-8
DOI 10.1161/STROKEAHA.115.009592, PubMed 26089332
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients
Hypertension, 66 (2), 368-73
DOI 10.1161/HYPERTENSIONAHA.115.05728, PubMed 26056336
Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design
Eur Heart J, 36 (33), 2219-27
DOI 10.1093/eurheartj/ehv192, PubMed 25990344
High screening blood pressure at young age predicts future masked hypertension: A 17 year follow-up study
Blood Press, 24 (3), 131-8
DOI 10.3109/21695717.2015.1030889, PubMed 25901999
Long-term survival in the randomized trial of drug treatment in mild to moderate hypertension of the Oslo study 1972-3
Eur J Intern Med, 26 (2), 123-6
DOI 10.1016/j.ejim.2015.01.013, PubMed 25681139
Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension
Front Physiol, 6, 9
DOI 10.3389/fphys.2015.00009, PubMed 25709581
Renal denervation in treatment-resistant hypertension: a reappraisal
Curr Opin Pharmacol, 21, 48-52
DOI 10.1016/j.coph.2014.12.013, PubMed 25601357
Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension
Blood Press, 24 (5), 263-74
DOI 10.3109/08037051.2015.1058595, PubMed 26194721
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial
J Clin Hypertens (Greenwich), 17 (2), 141-6
DOI 10.1111/jch.12460, PubMed 25529596
Hyperresponders vs. nonresponder patients after renal denervation: do they differ?
J Hypertens, 32 (12), 2422-7; discussion 2427
DOI 10.1097/HJH.0000000000000347, PubMed 25375391
Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results
J Hypertens, 32 (12), 2488-98; discussion 2498
DOI 10.1097/HJH.0000000000000331, PubMed 25144296
Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study
Eur J Prev Cardiol, 23 (1), 59-66
DOI 10.1177/2047487314553202, PubMed 25281482
[Questionable efficacy of renal denervation]
Tidsskr Nor Laegeforen, 134 (17), 1643-4
DOI 10.4045/tidsskr.14.0900, PubMed 25223668
Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture
Blood Press, 24 (1), 1-6
DOI 10.3109/08037051.2014.946787, PubMed 25162203
Renal denervation after Symplicity HTN-3: an update
Curr Hypertens Rep, 16 (8), 460
DOI 10.1007/s11906-014-0460-x, PubMed 24913923
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients
J Hum Hypertens, 28 (11), 663-9
DOI 10.1038/jhh.2014.43, PubMed 25211055
Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension
Curr Med Res Opin, 30 (9), 1715-24
DOI 10.1185/03007995.2014.924912, PubMed 24834808
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring
Drugs R D, 14 (2), 31-43
DOI 10.1007/s40268-014-0049-5, PubMed 24842751
Eligibility for renal denervation: experience at 11 European expert centers
Hypertension, 63 (6), 1319-25
DOI 10.1161/HYPERTENSIONAHA.114.03194, PubMed 24664290
Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension
Hypertension, 63 (5), 991-9
DOI 10.1161/HYPERTENSIONAHA.114.03246, PubMed 24591332
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy
Am J Hypertens, 27 (7), 966-72
DOI 10.1093/ajh/hpu006, PubMed 24552888
Heart rate as a predictor of stroke in high-risk, hypertensive patients with previous stroke or transient ischemic attack
J Stroke Cerebrovasc Dis, 23 (10), 2814-2818
DOI 10.1016/j.jstrokecerebrovasdis.2014.07.009, PubMed 25304725
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
Blood Press, 23 (1), 3-16
DOI 10.3109/08037051.2014.868629, PubMed 24359485
Blood pressure changes after renal denervation at 10 European expert centers
J Hum Hypertens, 28 (3), 150-6
DOI 10.1038/jhh.2013.88, PubMed 24067345
[Choice of drug in hypertension]
Tidsskr Nor Laegeforen, 133 (17), 1802-3
DOI 10.4045/tidsskr.13.0311, PubMed 24042290
[Hypertension in healthy people over 80 should be treated]
Tidsskr Nor Laegeforen, 133 (17), 1804-5
DOI 10.4045/tidsskr.13.0539, PubMed 24042291
Low heart rates predict incident atrial fibrillation in healthy middle-aged men
Circ Arrhythm Electrophysiol, 6 (4), 726-31
DOI 10.1161/CIRCEP.113.000267, PubMed 23873309
Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure
Hypertension, 62 (3), 526-32
DOI 10.1161/HYPERTENSIONAHA.113.01452, PubMed 23836798
Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Diabetes Res Clin Pract, 101 (2), 201-9
DOI 10.1016/j.diabres.2013.06.001, PubMed 23827210
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
J Hypertens, 31 (7), 1281-357
DOI 10.1097/01.hjh.0000431740.32696.cc, PubMed 23817082
An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors
Expert Rev Cardiovasc Ther, 11 (6), 673-82
DOI 10.1586/erc.13.63, PubMed 23750676
Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment
Blood Press, 23 (2), 71-80
DOI 10.3109/08037051.2013.791414, PubMed 23721506
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study
Diabet Med, 30 (10), 1189-97
DOI 10.1111/dme.12213, PubMed 23587029
Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients
J Clin Hypertens (Greenwich), 15 (6), 380-8
DOI 10.1111/jch.12089, PubMed 23730986
Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men
Hypertension, 61 (5), 1134-40
DOI 10.1161/HYPERTENSIONAHA.111.00793, PubMed 23529164
Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study
J Hypertens, 31 (3), 610-5; discussion 615
DOI 10.1097/HJH.0b013e32835d6e53, PubMed 23303395
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy
Circ Arrhythm Electrophysiol, 6 (2), 243-51
DOI 10.1161/CIRCEP.112.977777, PubMed 23403268
Hypertension and genetic variation in endothelial-specific genes
PLoS One, 8 (4), e62035
DOI 10.1371/journal.pone.0062035, PubMed 23637959
Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey
J Hum Hypertens, 27 (7), 412-6
DOI 10.1038/jhh.2012.61, PubMed 23235366
Troponin T is a better predictor than creatine kinase-MB of long-term mortality after coronary artery bypass graft surgery
Am Heart J, 164 (5), 779-85
DOI 10.1016/j.ahj.2012.05.027, PubMed 23137510
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
J Hypertens, 30 (11), 2213-22
DOI 10.1097/HJH.0b013e3283582ed6, PubMed 23011525
Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy
J Renin Angiotensin Aldosterone Syst, 14 (3), 227-34
DOI 10.1177/1470320312460292, PubMed 23077078
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study
Hypertension, 60 (2), 347-53
DOI 10.1161/HYPERTENSIONAHA.112.195032, PubMed 22753219
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study
Am J Hypertens, 25 (10), 1101-9
DOI 10.1038/ajh.2012.86, PubMed 22717544
Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms
J Hypertens, 30 (6), 1151-60
DOI 10.1097/HJH.0b013e3283536338, PubMed 22525200
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
J Hypertens, 30 (6), 1252-9
DOI 10.1097/HJH.0b013e328352f7f6, PubMed 22499288
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome
Stroke, 43 (8), 2108-14
DOI 10.1161/STROKEAHA.111.647362, PubMed 22627991
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men
Am J Cardiol, 110 (3), 425-32
DOI 10.1016/j.amjcard.2012.03.043, PubMed 22579085
ESH position paper: renal denervation - an interventional therapy of resistant hypertension
J Hypertens, 30 (5), 837-41
DOI 10.1097/HJH.0b013e328352ce78, PubMed 22469838
Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk
Eur J Prev Cardiol, 20 (4), 541-8
DOI 10.1177/2047487312444370, PubMed 22492865
Impact of lower achieved blood pressure on outcomes in hypertensive patients
J Hypertens, 30 (4), 802-10; discussion 810
DOI 10.1097/HJH.0b013e3283516499, PubMed 22343536
Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study
J Hum Hypertens, 27 (2), 100-6
DOI 10.1038/jhh.2012.4, PubMed 22336903
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study
Hypertension, 59 (2), 198-204
DOI 10.1161/HYPERTENSIONAHA.111.179713, PubMed 22252392
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium
Blood Press, 21 (3), 146-52
DOI 10.3109/08037051.2011.649537, PubMed 22243363
Sympathoadrenal Reactivity to Stress as a Predictor of Cardiovascular Risk Factors
J. Hyperton., 16 (2), 13-18
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Kidney Int, 81 (6), 568-76
DOI 10.1038/ki.2011.417, PubMed 22189843
Effect of changing heart rate during treatment of hypertension on incidence of heart failure
Am J Cardiol, 109 (5), 699-704
DOI 10.1016/j.amjcard.2011.10.026, PubMed 22154318
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension
Am J Cardiol, 109 (5), 685-92
DOI 10.1016/j.amjcard.2011.10.025, PubMed 22169130
Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men
J Intern Med, 271 (6), 581-8
DOI 10.1111/j.1365-2796.2011.02480.x, PubMed 22061296
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study
Blood Press, 21 (1), 6-11
DOI 10.3109/08037051.2011.622978, PubMed 22070095
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study
Heart Rhythm, 9 (4), 531-7
DOI 10.1016/j.hrthm.2011.11.008, PubMed 22079554
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
Atherosclerosis, 220 (1), 250-6
DOI 10.1016/j.atherosclerosis.2011.10.009, PubMed 22062589
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Blood Press, 21 (2), 82-7
DOI 10.3109/08037051.2011.598699, PubMed 21830844
Assessment of left ventricular function in ST-elevation myocardial infarction by global longitudinal strain: a comparison with ejection fraction, infarct size, and wall motion score index measured by non-invasive imaging modalities
Eur J Echocardiogr, 12 (9), 678-83
DOI 10.1093/ejechocard/jer113, PubMed 21810829
Effects of anthocyanins on blood pressure and stress reactivity: a double-blind randomized placebo-controlled crossover study
J Hum Hypertens, 26 (6), 396-404
DOI 10.1038/jhh.2011.41, PubMed 21544087
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy
J Hypertens, 29 (5), 997-1004
DOI 10.1097/HJH.0b013e328344daa3, PubMed 21358415
Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 3 months after myocardial infarction are more strongly associated with magnetic resonance-determined ejection fraction than NTproBNP levels in the acute phase
J Card Fail, 17 (6), 479-86
DOI 10.1016/j.cardfail.2011.02.006, PubMed 21624736
Echocardiographic demonstration of improved myocardial function early after coronary artery bypass graft surgery
Interact Cardiovasc Thorac Surg, 12 (6), 946-51
DOI 10.1510/icvts.2010.260414, PubMed 21422155
Racial differences in incident heart failure during antihypertensive therapy
Circ Cardiovasc Qual Outcomes, 4 (2), 157-64
DOI 10.1161/CIRCOUTCOMES.110.960112, PubMed 21304095
A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients
J Hypertens, 29 (2), 388-95
DOI 10.1097/HJH.0b013e3283410390, PubMed 21052022
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study
Eur J Heart Fail, 13 (4), 384-91
DOI 10.1093/eurjhf/hfq224, PubMed 21239405
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan
J Clin Hypertens (Greenwich), 13 (3), 189-97
DOI 10.1111/j.1751-7176.2010.00410.x, PubMed 21366850
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials
Lancet Oncol, 12 (1), 65-82
DOI 10.1016/S1470-2045(10)70260-6, PubMed 21123111
A link between hypertension and atrial fibrillation: methods of treatment and prevention
Curr Vasc Pharmacol, 8 (6), 769-74
DOI 10.2174/157016110793563807, PubMed 20626338
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension
PLoS Genet, 6 (10), e1001177
DOI 10.1371/journal.pgen.1001177, PubMed 21082022
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy
Eur Heart J, 31 (18), 2271-9
DOI 10.1093/eurheartj/ehq225, PubMed 20601389
Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy
Am Heart J, 160 (1), 73-9
DOI 10.1016/j.ahj.2010.04.011, PubMed 20598975
Cardiovascular events during differing hypertension therapies in patients with diabetes
J Am Coll Cardiol, 56 (1), 77-85
DOI 10.1016/j.jacc.2010.02.046, PubMed 20620720
Assessment of left ventricular function with magnetic resonance imaging vs. echocardiography, contrast echocardiography, and single-photon emission computed tomography in patients with recent ST-elevation myocardial infarction
Eur J Echocardiogr, 11 (9), 793-800
DOI 10.1093/ejechocard/jeq069, PubMed 20525984
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 28 (6), 1134-40
DOI 10.1097/HJH.0b013e328337a9c8, PubMed 20486280
The prognostic significance of heart rate for cardiovascular disease and hypertension
Curr Hypertens Rep, 12 (3), 162-9
DOI 10.1007/s11906-010-0104-8, PubMed 20431967
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study
Blood Press, 19 (3), 145-51
DOI 10.3109/08037051.2010.481812, PubMed 20429689
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study
J Hum Hypertens, 25 (3), 178-85
DOI 10.1038/jhh.2010.52, PubMed 20505749
Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis
J Am Coll Cardiol, 55 (21), 2299-307
DOI 10.1016/j.jacc.2010.01.043, PubMed 20488299
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study
Am J Hypertens, 23 (8), 845-51
DOI 10.1038/ajh.2010.89, PubMed 20431530
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients
Am J Hypertens, 23 (7), 786-93
DOI 10.1038/ajh.2010.65, PubMed 20395941
Health-care costs of losartan and candesartan in the primary treatment of hypertension
J Hum Hypertens, 25 (2), 130-6
DOI 10.1038/jhh.2010.36, PubMed 20376078
Interaction between inflammation and blood viscosity predicts cardiovascular mortality
Scand Cardiovasc J, 44 (2), 107-12
DOI 10.1080/14017430903171248, PubMed 19670036
European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2009; 10: No.42 Hypertension and Atrial Fibrillation with Emphasis on Prevention
J. Hyperton., 14 (3), 36-39
European guidelines on the management of hypertension: The European Society of Hypertension position statement (2009)
Arterial Hypertens, 14 (1), 1-47
Blood pressure development and hypertensive retinopathy: 20-year follow-up of middle-aged normotensive and hypertensive men
J Hum Hypertens, 24 (8), 505-13
DOI 10.1038/jhh.2009.94, PubMed 20010619
Time for new indications for statins?
Med Sci Monit, 15 (12), MS1-5
PubMed 19946240
Long-term stability of cardiovascular and catecholamine responses to stress tests: an 18-year follow-up study
Hypertension, 55 (1), 131-6
DOI 10.1161/HYPERTENSIONAHA.109.143164, PubMed 19948985
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
J Hum Hypertens, 24 (4), 263-73
DOI 10.1038/jhh.2009.77, PubMed 19890371
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study
J Hypertens, 27 (11), 2271-7
DOI 10.1097/HJH.0b013e328330b66b, PubMed 19834342
Blood pressure control and components of the metabolic syndrome: the GOOD survey
Cardiovasc Diabetol, 8, 51
DOI 10.1186/1475-2840-8-51, PubMed 19754934
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study
Eur Heart J, 30 (23), 2908-14
DOI 10.1093/eurheartj/ehp321, PubMed 19687165
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study
Nutr Metab Cardiovasc Dis, 19 (9), 634-40
DOI 10.1016/j.numecd.2008.12.012, PubMed 19361968
The myocardial infarction associated CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of coronary events in patients with hypertension
J Hypertens, 27 (4), 769-73
DOI 10.1097/HJH.0b013e328326f7eb, PubMed 19293724
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE)
Circulation, 119 (14), 1883-91
DOI 10.1161/CIRCULATIONAHA.108.812313, PubMed 19332468
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 27 (3), 567-74
DOI 10.1097/HJH.0b013e32831daf96, PubMed 19262226
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study
Blood Press, 18 (6), 348-61
DOI 10.3109/08037050903460590, PubMed 20001655
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study
Circ Arrhythm Electrophysiol, 1 (5), 337-43
DOI 10.1161/CIRCEP.108.795351, PubMed 19808428
Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey
J Hum Hypertens, 23 (5), 316-24
DOI 10.1038/jhh.2008.136, PubMed 19005476
Serum phosphate, blood pressure, and the metabolic syndrome--20-year follow-up of middle-aged men
J Clin Hypertens (Greenwich), 10 (11), 814-21
DOI 10.1111/j.1751-7176.2008.00032.x, PubMed 19128269
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
J Hypertens, 26 (11), 2103-11
DOI 10.1097/HJH.0b013e328310e0d9, PubMed 18854748
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study
Am Heart J, 157 (1), 177-84
DOI 10.1016/j.ahj.2008.08.011, PubMed 19081416
Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey
J Hypertens, 26 (10), 2064-70
DOI 10.1097/HJH.0b013e32830c45c3, PubMed 18806632
Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study
Metabolism, 57 (10), 1422-7
DOI 10.1016/j.metabol.2008.05.012, PubMed 18803948
Cardiovascular protection for all individuals at high risk: evidence-based best practice
Clin Res Cardiol, 97 (10), 713-25
DOI 10.1007/s00392-008-0713-2, PubMed 18726243
Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study
Hypertension, 52 (2), 336-41
DOI 10.1161/HYPERTENSIONAHA.108.111625, PubMed 18574074
Does sympathoadrenal activity predict changes in body fat? An 18-y follow-up study
Am J Clin Nutr, 87 (6), 1596-601
DOI 10.1093/ajcn/87.6.1596, PubMed 18541545
Prevention of atrial fibrillation in hypertension
Curr Hypertens Rep, 10 (3), 175-81
DOI 10.1007/s11906-008-0034-x, PubMed 18765086
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study
J Hypertens, 26 (6), 1244-9
DOI 10.1097/HJH.0b013e3282fcc23c, PubMed 18475164
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial
J Hum Hypertens, 22 (8), 520-7
DOI 10.1038/jhh.2008.41, PubMed 18509347
Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy
Hypertension, 52 (1), 100-6
DOI 10.1161/HYPERTENSIONAHA.108.110064, PubMed 18504323
Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study
Hypertension, 52 (1), 115-22
DOI 10.1161/HYPERTENSIONAHA.107.109264, PubMed 18504324
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial
J Hypertens, 26 (3), 403-11
DOI 10.1097/HJH.0b013e3282f35c67, PubMed 18300848
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study
Hypertension, 51 (4), 1103-8
DOI 10.1161/HYPERTENSIONAHA.107.105296, PubMed 18259029
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study
Am J Hypertens, 21 (3), 273-9
DOI 10.1038/ajh.2007.66, PubMed 18219298
Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial)
Am J Cardiol, 101 (5), 634-8
DOI 10.1016/j.amjcard.2007.10.025, PubMed 18308012
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure
Eur Heart J, 29 (4), 499-508
DOI 10.1093/eurheartj/ehm583, PubMed 18175773
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial
Blood Press, 17 (3), 170-7
DOI 10.1080/08037050802169644, PubMed 18608200
Do screening blood pressure and plasma catecholamines predict development of hypertension? Twenty-year follow-up of middle-aged men
Blood Press, 17 (2), 94-103
DOI 10.1080/08037050801972923, PubMed 18568698
Tissue Doppler imaging describes diastolic function in men prone to develop hypertension over twenty years
Eur J Echocardiogr, 9 (1), 34-9
DOI 10.1016/j.euje.2007.02.007, PubMed 17448731
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
Blood Press, 17 (1), 7-17
DOI 10.1080/08037050801972857, PubMed 18568687
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade
Blood Press, 17 (3), 156-63
DOI 10.1080/08037050802162847, PubMed 18608197
Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity
Metabolism, 56 (11), 1470-7
DOI 10.1016/j.metabol.2007.06.012, PubMed 17950096
The evolution of ACE inhibition--a turning point in cardiovascular medicine
Blood Press Suppl, 2, 5-6
DOI 10.1080/08038020701538313, PubMed 18046972
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study
J Intern Med, 262 (4), 439-48
DOI 10.1111/j.1365-2796.2007.01808.x, PubMed 17875180
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Hypertension, 50 (5), 984-90
DOI 10.1161/HYPERTENSIONAHA.107.096818, PubMed 17893425
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients
Ann Intern Med, 147 (5), 311-9
DOI 10.7326/0003-4819-147-5-200709040-00006, PubMed 17785486
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
J Hypertens, 25 (9), 1751-62
DOI 10.1097/HJH.0b013e3282f0580f, PubMed 17762635
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)
Eur J Cardiovasc Prev Rehabil, 14 Suppl 2, E1-40
DOI 10.1097/01.hjr.0000277984.31558.c4, PubMed 17726406
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)
Eur J Cardiovasc Prev Rehabil, 14 Suppl 2, S1-113
DOI 10.1097/01.hjr.0000277983.23934.c9, PubMed 17726407
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action
J Hum Hypertens, 22 (1), 63-70
DOI 10.1038/sj.jhh.1002284, PubMed 17728797
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population
Hypertension, 50 (3), 467-73
DOI 10.1161/HYPERTENSIONAHA.106.085654, PubMed 17679652
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study
Circulation, 116 (7), 700-5
DOI 10.1161/CIRCULATIONAHA.106.666594, PubMed 17664372
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study)
Am J Cardiol, 100 (5), 855-9
DOI 10.1016/j.amjcard.2007.03.109, PubMed 17719333
Guidelines 2007 Guidelines for the treatment of hypertension by the Committee for the drafting of the Guidelines of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)
G. Ital. Cardiol., 8 (7), 389-479
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
J Hypertens, 25 (6), 1105-87
DOI 10.1097/HJH.0b013e3281fc975a, PubMed 17563527
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study
J Hum Hypertens, 21 (8), 625-32
DOI 10.1038/sj.jhh.1002203, PubMed 17476291
Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years
J Clin Hypertens (Greenwich), 9 (5), 365-71
DOI 10.1111/j.1524-6175.2007.06479.x, PubMed 17485972
Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia
Metabolism, 56 (4), 464-9
DOI 10.1016/j.metabol.2006.11.003, PubMed 17379002
Personality may influence reactivity to stress
Biopsychosoc Med, 1, 5
DOI 10.1186/1751-0759-1-5, PubMed 17371575
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy
J Hypertens, 25 (3), 707-12
DOI 10.1097/HJH.0b013e3280147119, PubMed 17278988
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine
J Hum Hypertens, 21 (5), 374-80
DOI 10.1038/sj.jhh.1002159, PubMed 17314999
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy
Curr Med Res Opin, 23 (2), 259-70
DOI 10.1185/030079906X162854, PubMed 17288679
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Blood Press, 16 (1), 6-12
DOI 10.1080/08037050701246386, PubMed 17453746
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients
J Cardiovasc Pharmacol, 49 (1), 27-32
DOI 10.1097/FJC.0b013e31802bdd8c, PubMed 17261960
2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Blood Press, 16 (3), 135-232
DOI 10.1080/08037050701461084, PubMed 17846925
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
Blood Press, 16 (1), 13-9
DOI 10.1080/08037050701217643, PubMed 17453747
Increased hematocrit before blood pressure in men who develop hypertension over 20 years
J Am Soc Hypertens, 1 (6), 400-6
DOI 10.1016/j.jash.2007.07.002, PubMed 20409872
Exceptional early blood pressure control rates: the ACCOMPLISH trial
Blood Press, 16 (2), 80-6
DOI 10.1080/08037050701395571, PubMed 17612905
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
Eur Heart J, 27 (24), 2982-8
DOI 10.1093/eurheartj/ehl403, PubMed 17145722
Scintigraphic demonstration of myocardial perfusion and ischaemia associated with coronary artery bypass grafting
Scand Cardiovasc J, 40 (6), 354-62
DOI 10.1080/14017430601004063, PubMed 17118826
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial
J Hypertens, 24 (11), 2163-8
DOI 10.1097/01.hjh.0000249692.96488.46, PubMed 17053536
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors
J Hum Hypertens, 20 (11), 860-6
DOI 10.1038/sj.jhh.1002087, PubMed 16988754
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
JAMA, 296 (10), 1242-8
DOI 10.1001/jama.296.10.1242, PubMed 16968848
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
J Hypertens, 24 (8), 1531-9
DOI 10.1097/01.hjh.0000239288.10013.04, PubMed 16877955
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy
Hypertension, 48 (3), 385-91
DOI 10.1161/01.HYP.0000236119.96301.f2, PubMed 16864741
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
J Hypertens, 24 (7), 1405-12
DOI 10.1097/01.hjh.0000234122.55895.5b, PubMed 16794491
Are all the hypertensives made equal?
Herz, 31 (4), 323-30
DOI 10.1007/s00059-006-2782-1, PubMed 16810472
ESH-ESC guidelines for the management of hypertension
Herz, 31 (4), 331-8
DOI 10.1007/s00059-006-2829-3, PubMed 16810473
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study
J Hum Hypertens, 20 (6), 460-4
DOI 10.1038/sj.jhh.1002013, PubMed 16572193
Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years
J Hypertens, 24 (5), 905-13
DOI 10.1097/01.hjh.0000222761.07477.7b, PubMed 16612253
Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting
J Hypertens, 24 (4), 603-10
DOI 10.1097/01.hjh.0000217838.49842.1e, PubMed 16531784
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study
J Hypertens, 24 (4), 775-81
DOI 10.1097/01.hjh.0000217862.50735.dc, PubMed 16531808
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
Circulation, 113 (12), 1588-96
DOI 10.1161/CIRCULATIONAHA.105.574822, PubMed 16534012
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy
J Clin Hypertens (Greenwich), 8 (3), 169-73
DOI 10.1111/j.1524-6175.2006.04838.x, PubMed 16522993
Sympathetic activity and cardiovascular risk factors in young men in the low, normal, and high blood pressure ranges
Hypertension, 47 (3), 396-402
DOI 10.1161/01.HYP.0000203952.27988.79, PubMed 16446389
N-terminal pro-B-type natriuretic peptide in risk stratification after acute myocardial infarction in patients on long-term beta-adrenergic receptor blocker therapy
Cardiology, 106 (2), 102-8
DOI 10.1159/000092743, PubMed 16636540
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy
Blood Press, 15 (4), 198-206
DOI 10.1080/08037050600962968, PubMed 17078155
Is there an association between severe job strain, transient rise in blood pressure and increased mortality?
Blood Press, 15 (2), 93-100
DOI 10.1080/08037050600750157, PubMed 16754272
Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
Circulation, 113 (1), 67-73
DOI 10.1161/CIRCULATIONAHA.105.569491, PubMed 16365195
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
Lancet, 366 (9489), 907-13
DOI 10.1016/S0140-6736(05)67186-3, PubMed 16154017
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Lancet, 366 (9489), 895-906
DOI 10.1016/S0140-6736(05)67185-1, PubMed 16154016
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study
J Am Coll Cardiol, 46 (5), 770-5
DOI 10.1016/j.jacc.2005.05.060, PubMed 16139123
Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005
J Am Soc Nephrol, 16 (9), 2521-2527
DOI 10.1681/01.asn.0000926736.37167.bd, PubMed 36996483
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy
Hypertension, 46 (3), 492-9
DOI 10.1161/01.HYP.0000179604.42845.8d, PubMed 16116047
Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005
J Am Soc Nephrol, 16 (8), 2247-2250
DOI 10.1681/01.asn.0000926732.38641.89, PubMed 36996478
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
Diabetes Care, 28 (5), 1151-7
DOI 10.2337/diacare.28.5.1151, PubMed 15855581
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study
Circulation, 111 (15), 1924-31
DOI 10.1161/01.CIR.0000161799.91577.0A, PubMed 15837945
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy
Hypertension, 45 (4), 580-5
DOI 10.1161/01.HYP.0000161186.55933.6b, PubMed 15790960
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy
J Hypertens, 23 (4), 891-8
DOI 10.1097/01.hjh.0000163160.60234.15, PubMed 15775796
Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy
J Hum Hypertens, 19 (4), 301-7
DOI 10.1038/sj.jhh.1001819, PubMed 15647776
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol, 45 (5), 705-11
DOI 10.1016/j.jacc.2004.06.080, PubMed 15734614
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
J Am Coll Cardiol, 45 (5), 712-9
DOI 10.1016/j.jacc.2004.10.068, PubMed 15734615
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study
J Clin Hypertens (Greenwich), 7 (3), 152-8
DOI 10.1111/j.1524-6175.2005.04254.x, PubMed 15785156
[Misinterpretation of research]
Tidsskr Nor Laegeforen, 125 (3), 327
PubMed 15702162
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
Hypertension, 45 (2), 198-202
DOI 10.1161/01.HYP.0000154082.72286.2a, PubMed 15655123
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients
Cardiology, 103 (3), 148-55
DOI 10.1159/000084584, PubMed 15785019
Blood viscosity: effects of mental stress and relations to autonomic nervous system function and insulin sensitivity
Blood Press, 14 (3), 159-69
DOI 10.1080/08037050510034176, PubMed 16036496
ASCOT - more than a horse race!
Blood Press, 14 (5), 262-3
DOI 10.1080/08037050500350942, PubMed 16257870
Adrenaline during mental stress in relation to fitness, metabolic risk factors and cardiovascular responses in young men
Blood Press, 14 (4), 217-26
DOI 10.1080/08037050510034275, PubMed 16126555
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study
Hypertension, 45 (1), 46-52
DOI 10.1161/01.HYP.0000151324.05355.1c, PubMed 15583076
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
JAMA, 292 (19), 2343-9
DOI 10.1001/jama.292.19.2343, PubMed 15547161
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Am Heart J, 148 (5), 747-54
DOI 10.1016/j.ahj.2004.04.037, PubMed 15523303
[Failing basis for the use of thiazides]
Tidsskr Nor Laegeforen, 124 (20), 2659-60
PubMed 15534650
Relations between insulin sensitivity, fitness and autonomic cardiac regulation in healthy, young men
J Hypertens, 22 (10), 2007-15
DOI 10.1097/00004872-200410000-00025, PubMed 15361774
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
J Hypertens, 22 (9), 1805-11
DOI 10.1097/00004872-200409000-00026, PubMed 15311110
Adrenal medullary overactivity in lean, borderline hypertensive young men
Am J Hypertens, 17 (7), 611-8
DOI 10.1016/j.amjhyper.2004.03.676, PubMed 15233980
[Prevention of myocardial infarction and stroke with statins]
Tidsskr Nor Laegeforen, 124 (13-14), 1821
PubMed 15229678
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
Lancet, 363 (9426), 2049-51
DOI 10.1016/S0140-6736(04)16456-8, PubMed 15207957
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Lancet, 363 (9426), 2022-31
DOI 10.1016/S0140-6736(04)16451-9, PubMed 15207952
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients
Hypertension, 44 (1), 48-54
DOI 10.1161/01.HYP.0000132556.91792.6a, PubMed 15173125
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study
J Hum Hypertens, 18 (6), 403-9
DOI 10.1038/sj.jhh.1001707, PubMed 15057252
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy
J Hum Hypertens, 18 (6), 375-80
DOI 10.1038/sj.jhh.1001712, PubMed 15057253
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study
J Hum Hypertens, 18 (6), 381-9
DOI 10.1038/sj.jhh.1001731, PubMed 15103313
[Treatment of hypertension in patients with left ventricular hypertrophy]
Tidsskr Nor Laegeforen, 124 (6), 788-91
PubMed 15039810
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study
J Am Coll Cardiol, 43 (6), 1047-55
DOI 10.1016/j.jacc.2003.11.029, PubMed 15028365
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
Kidney Int, 65 (3), 1041-9
DOI 10.1111/j.1523-1755.2004.00484.x, PubMed 14871425
[Statin therapy for hypertensive patients]
Tidsskr Nor Laegeforen, 124 (2), 165-6
PubMed 14743227
High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men
Blood Press, 13 (2), 89-94
DOI 10.1080/08037050310031008, PubMed 15182111
Plasma catecholamines, blood pressure responses and perceived stress during mental arithmetic stress in young men
Blood Press, 13 (5), 287-94
DOI 10.1080/08037050410016474, PubMed 15545152
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study
Blood Press, 13 (6), 376-84
DOI 10.1080/08037050410016483, PubMed 15771223
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Drugs, 64 Suppl 2, 43-60
DOI 10.2165/00003495-200464002-00005, PubMed 15765890
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
Ann Intern Med, 139 (11), 901-6
DOI 10.7326/0003-4819-139-11-200312020-00008, PubMed 14644892
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines
J Hypertens, 21 (10), 1779-86
DOI 10.1097/01.hjh.0000084773.37215.1b, PubMed 14508180
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial
Ann Intern Med, 139 (3), 169-77
DOI 10.7326/0003-4819-139-3-200308050-00006, PubMed 12899584
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study
Circulation, 108 (6), 684-90
DOI 10.1161/01.CIR.0000083724.28630.C3, PubMed 12885747
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure
J Hypertens, 21 (7), 1383-9
DOI 10.1097/00004872-200307000-00029, PubMed 12817188
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
Am J Hypertens, 16 (7), 544-8
DOI 10.1016/s0895-7061(03)00904-x, PubMed 12850387
Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy
J Hum Hypertens, 17 (5), 305-11
DOI 10.1038/sj.jhh.1001545, PubMed 12756402
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet, 361 (9364), 1149-58
DOI 10.1016/S0140-6736(03)12948-0, PubMed 12686036
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study
Clin Ther, 25 (4), 1186-99
DOI 10.1016/s0149-2918(03)80075-9, PubMed 12809965
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]
Ugeskr Laeger, 165 (5), 456-9
PubMed 12599843
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]
Ugeskr Laeger, 165 (5), 459-62
PubMed 12599844
1999 WHO/ISH Hypertension Guidelines--highlights & ESH Update
Blood Press, 12 (3), 181-2
PubMed 12875481
Home blood pressure monitoring
Blood Press, 12 (3), 187-8
PubMed 12875484
Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy
Blood Press, 12 (2), 104-10
DOI 10.1080/08037050310060508, PubMed 12797630
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy
JAMA, 288 (12), 1491-8
DOI 10.1001/jama.288.12.1491, PubMed 12243636
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
J Hypertens, 20 (9), 1879-86
DOI 10.1097/00004872-200209000-00035, PubMed 12195132
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction
J Hum Hypertens, 16 (8), 591-5
DOI 10.1038/sj.jhh.1001450, PubMed 12149666
Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study
J Hypertens, 20 (6), 1231-7
DOI 10.1097/00004872-200206000-00038, PubMed 12023696
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet, 359 (9311), 995-1003
DOI 10.1016/S0140-6736(02)08089-3, PubMed 11937178
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet, 359 (9311), 1004-10
DOI 10.1016/S0140-6736(02)08090-X, PubMed 11937179
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study
J Hypertens, 20 (3), 405-12
DOI 10.1097/00004872-200203000-00015, PubMed 11875307
Early versus late morning measurement of blood pressure in healthy men. A potential source of measurement bias?
Blood Press, 11 (6), 366-70
DOI 10.1080/080370502321095339, PubMed 12523680
Comparison of home and office blood pressure in treated hypertensives in the Nordic Diltiazem (NORDIL) Study
Blood Press, 11 (6), 371-6
DOI 10.1080/080370502321095348, PubMed 12523681
1999 WHO/ISH Hypertension Guidelines--highlights & ESH update
J Hypertens, 20 (1), 153-5
DOI 10.1097/00004872-200201000-00022, PubMed 11791039
Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction
Blood Press, 11 (6), 377-84
DOI 10.1080/080370502321095357, PubMed 12523682
1999 WHO/ISH hypertension guidelines--highlights and esh update
J Hypertens, 19 (12), 2285-8
DOI 10.1097/00004872-200112000-00026, PubMed 11725177
Glucose disposal rates calculated from 60- to 90-minute isoglycemic hyperinsulinemic glucose clamp correlate with cardiovascular risk factors in borderline hypertensive young men
Metabolism, 50 (10), 1175-80
DOI 10.1053/meta.2001.26761, PubMed 11586489
Gender specific sympathetic and hemorrheological responses to mental stress in healthy young subjects
Scand Cardiovasc J, 35 (5), 307-12
DOI 10.1080/140174301317116271, PubMed 11771821
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study
Am J Hypertens, 14 (8 Pt 1), 775-82
DOI 10.1016/s0895-7061(01)01291-2, PubMed 11497193
Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point
J Am Coll Cardiol, 38 (2), 514-20
DOI 10.1016/s0735-1097(01)01378-x, PubMed 11499746
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol
J Hum Hypertens, 15 Suppl 1, S11-2
DOI 10.1038/sj.jhh.1001212, PubMed 11685901
Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men
J Hypertens, 19 (8), 1343-8
DOI 10.1097/00004872-200108000-00001, PubMed 11518841
Biphasic effect of epinephrine on blood glucose during hyperinsulinemia in borderline hypertensive young men
Am J Hypertens, 14 (6 Pt 1), 539-45
DOI 10.1016/s0895-7061(00)01306-6, PubMed 11411733
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators
J Hypertens, 19 (6), 1139-47
DOI 10.1097/00004872-200106000-00020, PubMed 11403364
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group
J Hypertens, 19 (6), 1149-59
DOI 10.1097/00004872-200106000-00021, PubMed 11403365
[Comparison of preventive effect of "new" and "old" antihypertensive agents]
Tidsskr Nor Laegeforen, 121 (11), 1374-6
PubMed 11419108
Polymorphisms in candidate genes for blood pressure regulation in young men with normal or elevated screening blood pressure
Blood Press, 10 (2), 92-100
DOI 10.1080/08037050152112078, PubMed 11467765
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation
Blood Press, 10 (2), 83-91
DOI 10.1080/08037050152112069, PubMed 11467764
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators
Hypertension, 36 (5), 766-73
DOI 10.1161/01.hyp.36.5.766, PubMed 11082141
Treatment of hypertension in patients with type-2 diabetes mellitus
J Hypertens, 18 (9), 1345-6
DOI 10.1097/00004872-200018090-00023, PubMed 10994767
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint
Am J Hypertens, 13 (8), 899-906
DOI 10.1016/s0895-7061(00)00280-6, PubMed 10950398
Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
Lancet, 356 (9227), 359-65
DOI 10.1016/s0140-6736(00)02526-5, PubMed 10972367
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment
J Hypertens, 18 (5), 629-42
DOI 10.1097/00004872-200018050-00017, PubMed 10826567
Self-measurement of blood pressure in clinical trials and therapeutic applications
Blood Press Monit, 5 (2), 145-9
PubMed 10828901
Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia
J Hypertens, 18 (1), 75-81
DOI 10.1097/00004872-200018010-00011, PubMed 10678546
Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study
J Gend Specif Med, 3 (8), 35-8
PubMed 11253266
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study
Hypertension, 35 (1 Pt 1), 13-8
DOI 10.1161/01.hyp.35.1.13, PubMed 10642268
Blood viscosity, plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy. ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica
Blood Press, 9 (2-3), 83-90
DOI 10.1080/08037050050151771, PubMed 10855729
Effects of hyperinsulinemia on sympathetic responses to mental stress
Am J Hypertens, 13 (1 Pt 1), 21-8
DOI 10.1016/s0895-7061(99)00146-6, PubMed 10678267
Treatment of hypertension in patients with type-2 diabetes mellitus
Blood Press, 9 (6), 363-4
PubMed 11212066
Assessment of insulin sensitivity by 90 min isoglycaemic hyperinsulinaemic glucose clamp in healthy young men
Blood Press, 9 (2-3), 121-5
DOI 10.1080/080370500453456, PubMed 10855735
Insulin sensitivity is related to physical fitness and exercise blood pressure to structural vascular properties in young men
Hypertension, 33 (3), 781-6
DOI 10.1161/01.hyp.33.3.781, PubMed 10082487
Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension
Blood Press, 8 (4), 214-9
DOI 10.1080/080370599439599, PubMed 10697301
Increased forearm blood flow during glucose clamp is related neither to insulin sensitivity nor to hyperinsulinemia in borderline hypertensive young men
Blood Press, 8 (4), 227-32
DOI 10.1080/080370599439616, PubMed 10697303
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension
Hypertension, 32 (6), 989-97
DOI 10.1161/01.hyp.32.6.989, PubMed 9856962
Relationship between insulin sensitivity and maximal forearm blood flow in young men
Hypertension, 32 (5), 838-43
DOI 10.1161/01.hyp.32.5.838, PubMed 9822441
Insulin modifies the glucose response to mental stress independently of forearm blood flow
Blood Press, 7 (5-6), 291-8
DOI 10.1080/080370598437150, PubMed 10321442
[Therapeutic targets for hypertension in the new media. An optimal antihypertensive therapy]
Tidsskr Nor Laegeforen, 118 (23), 3665
PubMed 9820015
Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects
Hypertension, 31 (4), 1014-20
DOI 10.1161/01.hyp.31.4.1014, PubMed 9535429
Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo
Metabolism, 47 (3), 292-6
DOI 10.1016/s0026-0495(98)90259-1, PubMed 9500565
Whole-blood viscosity and the insulin-resistance syndrome
J Hypertens, 16 (2), 203-10
DOI 10.1097/00004872-199816020-00011, PubMed 9535148
Clustering of coronary risk factors with increasing blood pressure at rest and during exercise
J Hypertens, 16 (1), 19-22
DOI 10.1097/00004872-199816010-00004, PubMed 9533412
Seasonal covariation in physical fitness and blood pressure at rest and during exercise in healthy middle-aged men
Blood Press, 6 (5), 269-73
DOI 10.3109/08037059709062081, PubMed 9359996
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
Am J Hypertens, 10 (7 Pt 1), 705-13
PubMed 9234823
Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors
Blood Press, 6 (3), 161-5
DOI 10.3109/08037059709061932, PubMed 9181254
Predictors of 7-year changes in exercise blood pressure: effects of smoking, physical fitness and pulmonary function
J Hypertens, 15 (3), 245-9
DOI 10.1097/00004872-199715030-00005, PubMed 9468451
Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique
Blood Press Suppl, 2, 113-9
PubMed 9495639
[Home blood pressure measurement in general practice patients]
Tidsskr Nor Laegeforen, 116 (21), 2566-9
PubMed 8928127
The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity
J Hypertens, 14 (9), 1093-7
DOI 10.1097/00004872-199609000-00008, PubMed 8986909
Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension
Hypertension, 27 (6), 1299-304
DOI 10.1161/01.hyp.27.6.1299, PubMed 8641739
Exercise blood pressure predicts mortality from myocardial infarction
Hypertension, 27 (3 Pt 1), 324-9
DOI 10.1161/01.hyp.27.3.324, PubMed 8698433
[Calcium antagonists in the treatment of hypertension and heart failure. A comment to recently published results of clinical trials]
Tidsskr Nor Laegeforen, 116 (1), 77-80
PubMed 8553344
[Effect of 1-alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men]
Tidsskr Nor Laegeforen, 116 (1), 37-40
PubMed 8553333
[Status of ongoing controlled clinical trials on hypertension]
Tidsskr Nor Laegeforen, 116 (1), 61-3
PubMed 8553340
Metabolic and adrenergic characteristics of young men with insulin resistance
Blood Press Suppl, 1, 30-7
PubMed 9162435
Effects of increased arterial epinephrine on insulin, glucose and phosphate
Blood Press, 5 (1), 27-31
DOI 10.3109/08037059609062103, PubMed 8777469
The glucose clamp procedure activates the sympathetic nervous system even in the absence of hyperinsulinemia
J Clin Endocrinol Metab, 80 (11), 3151-4
DOI 10.1210/jcem.80.11.7593418, PubMed 7593418
Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity?
J Hum Hypertens, 9 Suppl 5, S45-50
PubMed 8583481
Mental stress increases glucose uptake during hyperinsulinemia: associations with sympathetic and cardiovascular responsiveness
Metabolism, 44 (10), 1303-7
DOI 10.1016/0026-0495(95)90034-9, PubMed 7476289
Insulin resistance and sympathetic nervous system activity in hypertensive and normotensive premenopausal women
Blood Press, 4 (5), 287-92
DOI 10.3109/08037059509077609, PubMed 8535550
Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension
Am J Hypertens, 8 (7), 704-11
DOI 10.1016/0895-7061(95)00122-6, PubMed 7546496
Relationship between hemorheological factors and insulin sensitivity in normotensive and hypertensive premenopausal women
Am J Hypertens, 8 (5 Pt 1), 439-44
DOI 10.1016/0895-7061(95)00044-P, PubMed 7662218
Effect of circulating epinephrine on platelet function and hematocrit
Hypertension, 25 (5), 1096-105
DOI 10.1161/01.hyp.25.5.1096, PubMed 7737722
Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men
Am J Hypertens, 8 (3), 268-75
DOI 10.1016/0895-7061(94)00206-Q, PubMed 7794576
Quality of life on enalapril after acute myocardial infarction
Eur Heart J, 15 (8), 1135-9
DOI 10.1093/oxfordjournals.eurheartj.a060640, PubMed 7988608
Exercise blood pressure predicts cardiovascular mortality in middle-aged men
Hypertension, 24 (1), 56-62
DOI 10.1161/01.hyp.24.1.56, PubMed 8021008
Effect of alpha 1-adrenoceptor blockade on maximal VO2 and endurance capacity in well-trained athletic hypertensive men
Am J Hypertens, 7 (7 Pt 1), 603-8
DOI 10.1093/ajh/7.7.603, PubMed 7946161
[Treatment of hypertension in 1994. Comments on the 1993 guidelines of the Norwegian Society of General Practitioners concerning the treatment program for hypertension]
Tidsskr Nor Laegeforen, 114 (17), 1990-2
PubMed 8079331
The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension
Blood Press, 3 (3), 185-8
DOI 10.3109/08037059409102250, PubMed 8069407
Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness
Blood Press, 3 (3), 164-71
DOI 10.3109/08037059409102247, PubMed 8069404
Relationship between hemorrheologic factors and insulin sensitivity in healthy young men
Metabolism, 43 (4), 423-7
DOI 10.1016/0026-0495(94)90070-1, PubMed 8159097
Cardiovascular reactivity, coronary risk factors, and sympathetic activity in young men
Hypertension, 22 (6), 891-9
DOI 10.1161/01.hyp.22.6.891, PubMed 8244522
Effect of cold pressor test and awareness of hypertension on platelet function in normotensive and hypertensive women
Scand J Clin Lab Invest, 53 (6), 585-91
DOI 10.3109/00365519309092557, PubMed 8266004
Effects of ovarian stimulation on blood pressure and plasma catecholamine levels
Scand J Clin Lab Invest, 53 (4), 353-8
DOI 10.3109/00365519309086627, PubMed 8378738
[White coat hypertension and blood pressure measurement at home]
Tidsskr Nor Laegeforen, 113 (15), 1839-43
PubMed 8322321
Contrasting effects of epinephrine on forearm hemodynamics and arterial plasma norepinephrine
Am J Hypertens, 6 (5 Pt 1), 369-75
DOI 10.1093/ajh/6.5.369, PubMed 8512661
Evaluation of self-measured home vs. clinic intra-arterial blood pressure
Blood Press, 2 (1), 28-34
DOI 10.3109/08037059309077523, PubMed 8193727
Sex differences in essential hypertension
J Intern Med, 233 (1), 13-9
DOI 10.1111/j.1365-2796.1993.tb00641.x, PubMed 8429281
Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men
Gynecol Obstet Invest, 36 (4), 234-8
DOI 10.1159/000292636, PubMed 8300009
Mild essential hypertension in nonobese premenopausal women is characterized by low renin
Am J Hypertens, 5 (9), 579-84
DOI 10.1093/ajh/5.9.579, PubMed 1418846
Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril
Am Heart J, 123 (5), 1433-8
DOI 10.1016/0002-8703(92)91066-a, PubMed 1575171
Haemodynamic and neurohumoral effects of cold pressor test in severe heart failure
Clin Physiol, 12 (1), 95-106
DOI 10.1111/j.1475-097x.1992.tb00296.x, PubMed 1541087
[Ambulatory non-invasive 24-hour blood pressure measurement--do we need it?]
Tidsskr Nor Laegeforen, 111 (18), 2280-2
PubMed 1896989
The epinephrine-blood platelet connection with special reference to essential hypertension
Am Heart J, 122 (1 Pt 2), 330-6
DOI 10.1016/0002-8703(91)90843-7, PubMed 2053554
Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection
Br J Clin Pharmacol, 31 (6), 677-81
DOI 10.1111/j.1365-2125.1991.tb05592.x, PubMed 1867961
Hyperkinetic borderline hypertension in Tecumseh, Michigan
J Hypertens, 9 (1), 77-84
DOI 10.1097/00004872-199101000-00012, PubMed 1848264
Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor
J Cardiovasc Pharmacol, 17 (1), 13-9
DOI 10.1097/00005344-199101000-00003, PubMed 1708046
Awareness of hypertension increases blood pressure and sympathetic responses to cold pressor test
Am J Hypertens, 3 (12 Pt 1), 912-7
DOI 10.1093/ajh/3.12.912, PubMed 2081012
"White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan
Hypertension, 16 (6), 617-23
DOI 10.1161/01.hyp.16.6.617, PubMed 2246029
Increased arterial adrenaline is related to pain in uncomplicated myocardial infarction
J Intern Med, 228 (6), 617-22
DOI 10.1111/j.1365-2796.1990.tb00288.x, PubMed 2149143
Renal haemodynamic and sympathetic responses to head-up tilt in essential hypertension
Scand J Clin Lab Invest, 50 (8), 815-22
DOI 10.3109/00365519009104947, PubMed 2084819
Correlations between psychological and physiological responses to acute flight phobia stress
Scand J Clin Lab Invest, 50 (6), 671-7
DOI 10.3109/00365519009089186, PubMed 2247773
Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor
Clin Pharmacol Ther, 48 (1), 41-9
DOI 10.1038/clpt.1990.116, PubMed 2196144
Awareness of high blood pressure stimulates platelet release reaction
Thromb Haemost, 63 (3), 367-70
PubMed 2144919
Increased erythrocyte magnesium content in essential hypertension
Scand J Clin Lab Invest, 50 (4), 395-400
DOI 10.3109/00365519009091597, PubMed 2392652
Effects of beta 1- and beta 2-blockade on blood pressure and sympathetic responses to flight phobia stress
Clin Pharmacol Ther, 47 (5), 599-607
DOI 10.1038/clpt.1990.81, PubMed 1971540
Childhood traumas and psychosocial characteristics of 50-year-old men with essential hypertension
J Psychosom Res, 34 (6), 643-9
DOI 10.1016/0022-3999(90)90108-g, PubMed 2135736
Effects of selective beta-adrenoceptor blockade on anxiety associated with flight phobia
J Psychopharmacol, 4 (1), 35-41
DOI 10.1177/026988119000400106, PubMed 22282925
Increased erythrocyte magnesium in untreated essential hypertension
J Hypertens Suppl, 7 (6), S156-7
DOI 10.1097/00004872-198900076-00074, PubMed 2632702
Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension
Am Heart J, 118 (4), 775-81
DOI 10.1016/0002-8703(89)90592-9, PubMed 2801485
Effect of dopamine and dopamine-antagonist infusion on blood platelet count, size and release reaction in hypertensive and normotensive subjects
Scand J Clin Lab Invest, 49 (4), 307-15
DOI 10.3109/00365518909089102, PubMed 2525805
Plasma catecholamines in some airline passengers
Scand J Clin Lab Invest, 49 (2), 183-8
DOI 10.3109/00365518909105419, PubMed 2520371
Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise
Cardiovasc Drugs Ther, 3 (1), 63-71
DOI 10.1007/BF01881530, PubMed 2577280
Hyper-responsiveness to low-dose epinephrine infusion in mild essential hypertension
J Hypertens Suppl, 6 (4), S581-3
DOI 10.1097/00004872-198812040-00182, PubMed 3241257
Decreased platelet-free dopamine and unchanged noradrenaline and adrenaline in essential hypertension
Thromb Haemost, 60 (2), 251-4
PubMed 3217920
Decreased serum phosphate in essential hypertension. Related to increased sympathetic tone
Am J Hypertens, 1 (4 Pt 1), 403-9
DOI 10.1093/ajh/1.4.403, PubMed 3214562
[Non-pharmacological treatment of mild to moderate hypertension. A randomized, controlled study--results 1 1/2 years later]
Tidsskr Nor Laegeforen, 108 (22), 1593-7
PubMed 3046045
Sodium depletion increases platelet and plasma catecholamines in hypertensive men
Hypertension, 11 (5), 477-82
DOI 10.1161/01.hyp.11.5.477, PubMed 3366481
Increased platelet and vascular smooth muscle reactivity to low-dose adrenaline infusion in mild essential hypertension
J Hypertens, 6 (3), 219-25
DOI 10.1097/00004872-198803000-00006, PubMed 2966193
Plasma adrenaline: relations to blood pressure, blood platelet function and blood lipids in essential hypertension
Pharmacol Toxicol, 63 Suppl 1, 35-7
DOI 10.1111/j.1600-0773.1988.tb02036.x, PubMed 3200793
Myocardial potassium uptake and catecholamine release during cardiac sympathetic nerve stimulation
Cardiovasc Res, 21 (12), 892-901
DOI 10.1093/cvr/21.12.892, PubMed 3455356
The effects of naloxone and timolol on plasma catecholamine levels during short-term dynamic exercise
Scand J Clin Lab Invest, 47 (8), 847-51
PubMed 2893446
Does increased platelet release normalize during anti-hypertensive treatment?
Thromb Haemost, 58 (3), 834-8
PubMed 2963402
Increased platelet size and release reaction in essential hypertension
J Hypertens, 5 (4), 401-6
PubMed 2959720
Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension
Scand J Clin Lab Invest, 47 (4), 371-7
PubMed 3602915
[Sodium restriction in hypertension. Sympathetic tonus, renin and vasopressin]
Tidsskr Nor Laegeforen, 107 (10-11), 954-7
PubMed 3299859
Decreased central dopaminergic activity in essential hypertension
J Hypertens, 5 (2), 191-7
DOI 10.1097/00004872-198704000-00010, PubMed 3611768
Severe sodium restriction alone and with potassium supplementation does not alter blood lipoproteins in essential hypertension
Eur J Clin Invest, 17 (2), 182-6
DOI 10.1111/j.1365-2362.1987.tb02398.x, PubMed 3108006
Increased platelet release reaction in 50-year-old men with essential hypertension: correlation with atherogenic cholesterol fractions
Am Heart J, 113 (1), 151-5
DOI 10.1016/0002-8703(87)90023-8, PubMed 2948378
Aging and urinary vasopressin excretion in healthy men
Scand J Urol Nephrol, 21 (3), 235-9
DOI 10.3109/00365598709180328, PubMed 3433025
Increased plasma noradrenaline during severe sodium restriction does not stimulate platelet release in essential hypertension
Thromb Haemost, 56 (2), 120-3
PubMed 2949387
Plasma adrenaline and noradrenaline during orthostasis in man: the importance of arterial sampling
Scand J Clin Lab Invest, 46 (5), 397-401
DOI 10.3109/00365518609083689, PubMed 3749784
Enhanced platelet release reaction related to arterial plasma adrenaline and blood pressure in pre-eclampsia
Br J Obstet Gynaecol, 93 (6), 548-53
DOI 10.1111/j.1471-0528.1986.tb07952.x, PubMed 2942173
Increased plasma vasopressin in low renin essential hypertension
Hypertension, 8 (6), 506-13
DOI 10.1161/01.hyp.8.6.506, PubMed 2872161
The effect of sodium depletion and potassium supplementation on vasopressin, renin and catecholamines in hypertensive men
Acta Med Scand, 220 (3), 195-203
DOI 10.1111/j.0954-6820.1986.tb02751.x, PubMed 3535395
Hormonal responses to treatment of high blood pressure with low-salt diet alone and combined with added potassium
Acta Med Scand Suppl, 714, 93-7
DOI 10.1111/j.0954-6820.1986.tb08975.x, PubMed 3554904
Blood platelet release correlates with serum lipids in 50 year old men with essential hypertension
Acta Med Scand Suppl, 714, 125-8
DOI 10.1111/j.0954-6820.1986.tb08980.x, PubMed 2953173
Central dopaminergic control of prolactin in essential hypertension
Acta Med Scand Suppl, 714, 113-7
DOI 10.1111/j.0954-6820.1986.tb08978.x, PubMed 3472433
Increased arterial catecholamines in pre-eclampsia
Acta Obstet Gynecol Scand, 65 (6), 613-7
DOI 10.3109/00016348609158398, PubMed 3799158
Platelet volume, platelet release reaction and platelet response to infused adrenaline are increased in essential hypertension
Acta Med Scand Suppl, 714, 129-32
DOI 10.1111/j.0954-6820.1986.tb08981.x, PubMed 2953174
Serum phosphate and sympathetic tone in mild essential hypertension
Acta Med Scand Suppl, 714, 119-23
DOI 10.1111/j.0954-6820.1986.tb08979.x, PubMed 3472434
Increased arterial adrenaline is highly correlated to blood pressure and in vivo platelet function in pre-eclampsia
J Hypertens Suppl, 3 (3), S93-5
PubMed 2856791
Effects of adrenaline infusion on platelet number, volume and release reaction
Thromb Haemost, 54 (2), 450-3
PubMed 2417349
Dietary sodium intake increases vasopressin secretion in man
J Clin Hypertens, 1 (2), 123-31
PubMed 3915319
Evidence of age-related variation in plasma vasopressin of normotensive men
Scand J Clin Lab Invest, 45 (3), 263-8
DOI 10.3109/00365518509161004, PubMed 3890133
Adrenaline and preeclampsia
Acta Med Scand Suppl, 693, 29-32
DOI 10.1111/j.0954-6820.1985.tb08772.x, PubMed 3887855
Dietary sodium intake and vasopressin excretion in man
J Hypertens Suppl, 2 (3), S301-3
PubMed 6599675
[Pheochromocytoma. 2 cases diagnosed by newer technics]
Tidsskr Nor Laegeforen, 104 (32), 2244-7
PubMed 6523455
Arteriovenous difference of plasma vasopressin in normal man and effect of posture
Acta Physiol Scand, 122 (1), 49-53
DOI 10.1111/j.1748-1716.1984.tb07480.x, PubMed 6239521
Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension
Acta Med Scand, 215 (2), 165-72
DOI 10.1111/j.0954-6820.1984.tb04988.x, PubMed 6367368
Changes in the lipoprotein profile during antihypertensive therapy
Acta Pharmacol Toxicol (Copenh), 54 Suppl 1, 75-7
DOI 10.1111/j.1600-0773.1984.tb03637.x, PubMed 6711333
Influence of body weight on plasma catecholamine patterns in middle-aged, normotensive men
Scand J Clin Lab Invest, 43 (4), 339-42
PubMed 6635540
Increased arterial catecholamine concentrations in 50-year-old men with essential hypertension
Scand J Clin Lab Invest, 43 (4), 343-9
PubMed 6635541
Effects of posture on serum cholesterol fractions, cholesterol ratio and triglycerides
Scand J Clin Lab Invest, 43 (2), 119-21
PubMed 6577578
Decreased peripheral dopaminergic activity in essential hypertension?
Scand J Clin Lab Invest, 43 (1), 15-20
PubMed 6622964
Dopamine release from the porcine myocardium
Acta Physiol Scand, 119 (2), 197-201
DOI 10.1111/j.1748-1716.1983.tb07326.x, PubMed 6659987
Blood lipids and antihypertensive drugs. The Oslo study
J Pharmacol, 14 Suppl 2, 217-20
PubMed 6632918
Increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension
Acta Med Scand Suppl, 677, 17-20
DOI 10.1111/j.0954-6820.1984.tb08621.x, PubMed 6584000
Increased beta-thromboglobulin in essential hypertension: interactions between arterial plasma adrenaline, platelet function and blood lipids
Acta Med Scand, 213 (5), 369-73
DOI 10.1111/j.0954-6820.1983.tb03753.x, PubMed 6192689
Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension
Acta Med Scand, 214 (5), 367-71
DOI 10.1111/j.0954-6820.1983.tb08610.x, PubMed 6660046
Renal contribution to plasma catecholamines--effect of age
Scand J Clin Lab Invest, 42 (5), 461-6
PubMed 7156858
The effect on HDL cholesterol of oxprenolol and atenolol
Scand J Clin Lab Invest, 42 (5), 449-53
PubMed 6130595
Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension
Scand J Clin Lab Invest, 42 (3), 217-23
PubMed 7134805
Antihypertensive drugs and blood lipids: the Oslo study
J Cardiovasc Pharmacol, 4 Suppl 2, S222-4
PubMed 6177960
[Antihypertensive agents and blood lipids--The Oslo study]
Wien Med Wochenschr, 132 Spec No, 10-3
PubMed 7080512
Antihypertensive drugs and blood lipids: the Oslo study
Br J Clin Pharmacol, 13 (Suppl 2), 441S-444S
DOI 10.1111/j.1365-2125.1982.tb01954.x, PubMed 7104158
Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension?
Clin Sci (Lond), 61 Suppl 7, 215s-217s
DOI 10.1042/cs061215s, PubMed 7318326
[Hazards of benzodiazepine poisoning]
Tidsskr Nor Laegeforen, 99 (33), 1707-8
PubMed 43605
Review articles
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines
Hypertension, 81 (5), 1021-1030
DOI 10.1161/HYPERTENSIONAHA.124.22821, PubMed 38477109
The current best drug treatment for hypertensive heart failure with preserved ejection fraction
Eur J Intern Med, 120, 3-10
DOI 10.1016/j.ejim.2023.10.008, PubMed 37865559
Late outcomes of renal denervation are more favourable than early ones: facts or fancies?
Clin Kidney J, 16 (12), 2357-2364
DOI 10.1093/ckj/sfad231, PubMed 38046011
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
Blood Press, 31 (1), 210-224
DOI 10.1080/08037051.2022.2110858, PubMed 36029011
Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines
Hypertension, 79 (6), 1153-1166
DOI 10.1161/HYPERTENSIONAHA.122.19020, PubMed 35378981
Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis
Hypertension, 77 (2), 692-705
DOI 10.1161/HYPERTENSIONAHA.120.15781, PubMed 33390044
Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?
J Hypertens, 38 (8), 1396-1406
DOI 10.1097/HJH.0000000000002532, PubMed 32618895
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Hypertension, 75 (1), 23-32
DOI 10.1161/HYPERTENSIONAHA.119.14057, PubMed 31786973
The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?
J Hypertens, 37 (6), 1148-1153
DOI 10.1097/HJH.0000000000002021, PubMed 30624370
[Heart failure with preserved ejection fraction]
Tidsskr Nor Laegeforen, 139 (6)
DOI 10.4045/tidsskr.18.0523, PubMed 30917641
Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials
High Blood Press Cardiovasc Prev, 25 (2), 151-158
DOI 10.1007/s40292-018-0258-z, PubMed 29663195
Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis
J Hypertens, 36 (2), 221-229
DOI 10.1097/HJH.0000000000001582, PubMed 29045339
A critical review of the systolic blood pressure intervention trial (SPRINT)
Eur. Heart J., 38 (44), 3260-3265
Hypertension and cardiovascular risk: General aspects
Pharmacol Res, 129, 95-99
DOI 10.1016/j.phrs.2017.11.003, PubMed 29127059
The Un-Observed Automated Office Blood Pressure Measurement Technique Used in the SPRINT Study Points to a Standard Target Office Systolic Blood Pressure <140 mmHg
Curr Hypertens Rep, 19 (1), 3
DOI 10.1007/s11906-017-0700-y, PubMed 28091868
Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets
Blood Press, 25 (6), 333-336
DOI 10.1080/08037051.2016.1236329, PubMed 27644446
Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension
Hypertension, 68 (2), 297-306
DOI 10.1161/HYPERTENSIONAHA.116.07464, PubMed 27296995
Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials
Hypertension, 67 (5), 808-12
DOI 10.1161/HYPERTENSIONAHA.116.07257, PubMed 27001295
A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90mmHg
Prog Cardiovasc Dis, 59 (3), 209-218
DOI 10.1016/j.pcad.2016.09.002, PubMed 27619341
Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges
Curr Hypertens Rep, 18 (1), 6
DOI 10.1007/s11906-015-0610-9, PubMed 26739586
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
Eur Heart J, 37 (12), 955-64
DOI 10.1093/eurheartj/ehv633, PubMed 26590384
Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence
Eur Heart J Cardiovasc Pharmacother, 1 (1), 48-56
DOI 10.1093/ehjcvp/pvu009, PubMed 27533966
Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence
Eur Cardiol, 9 (2), 110-114
DOI 10.15420/ecr.2014.9.2.110, PubMed 30310496
Updated national and international hypertension guidelines: a review of current recommendations
Drugs, 74 (17), 2033-51
DOI 10.1007/s40265-014-0306-5, PubMed 25315030
Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure
Hypertension, 65 (1), 5-15
DOI 10.1161/HYPERTENSIONAHA.114.04057, PubMed 25350982
Renal sympathetic denervation in the aftermath of Symplicity HTN-3
Blood Press, 23 (5), 256-61
DOI 10.3109/08037051.2014.953861, PubMed 25212427
[Renal sympathetic denervation in treatment-resistant hypertension]
Tidsskr Nor Laegeforen, 134 (1), 32-6
DOI 10.4045/tidsskr.13.0276, PubMed 24429753
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension
J Am Coll Cardiol, 62 (22), 2031-45
DOI 10.1016/j.jacc.2013.08.1616, PubMed 24021387
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Eur Heart J, 34 (28), 2159-219
DOI 10.1093/eurheartj/eht151, PubMed 23771844
Updated ESH position paper on interventional therapy of resistant hypertension
EuroIntervention, 9 Suppl R, R58-66
DOI 10.4244/EIJV9SRA11, PubMed 23732157
Are fixed-dose combination antihypertensives suitable as first-line therapy?
Curr Med Res Opin, 28 (10), 1685-97
DOI 10.1185/03007995.2012.729505, PubMed 22978777
Treatment of hypertension in diabetes: what is the best therapeutic option?
Expert Rev Cardiovasc Ther, 10 (6), 727-34
DOI 10.1586/erc.12.59, PubMed 22894629
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension
J Hypertens, 30 (2), 239-52
DOI 10.1097/HJH.0b013e32834f03bf, PubMed 22186358
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?
Expert Opin Pharmacother, 12 (12), 1835-44
DOI 10.1517/14656566.2011.579106, PubMed 21517698
The role of beta-blockers in the treatment of chronic heart failure
Trends Pharmacol Sci, 32 (4), 206-12
DOI 10.1016/j.tips.2011.01.006, PubMed 21376403
Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension
Curr Med Res Opin, 26 (4), 879-87
DOI 10.1185/03007991003635178, PubMed 20144138
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
J Hypertens, 27 (11), 2121-58
DOI 10.1097/HJH.0b013e328333146d, PubMed 19838131
Role and significance of statins in the treatment of hypertensive patients
Curr Med Res Opin, 25 (8), 1995-2005
DOI 10.1185/03007990903098081, PubMed 19555312
Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension
J Hypertens, 27 (4), 673-9
DOI 10.1097/HJH.0b013e3283298ea2, PubMed 19516168
High heart rate as predictor of essential hypertension: the hyperkinetic state, evidence of prediction of hypertension, and hemodynamic transition to full hypertension
Prog Cardiovasc Dis, 52 (1), 20-5
DOI 10.1016/j.pcad.2009.05.008, PubMed 19615489
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
Blood Press, 18 (6), 308-47
DOI 10.3109/08037050903450468, PubMed 20001654
Hypertension and atrial fi brillation with emphasis on prevention
Blood Press, 18 (3), 94-8
DOI 10.1080/08037050903040744, PubMed 20499443
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective
Blood Press, 17 (5-6), 260-9
DOI 10.1080/08037050802565171, PubMed 19061055
The role of statins in patients with arterial hypertension
Arch. Med. Sci., 3 (4A), S97-S101
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]
Rev Esp Cardiol, 60 (9), 968.e1-94
DOI 10.1157/13109650, PubMed 17915153
[Practice guidelines 2007 for the treatment of arterial hypertension]
G Ital Cardiol (Rome), 8 (7), 389-479
PubMed 17695132
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Eur Heart J, 28 (12), 1462-536
DOI 10.1093/eurheartj/ehm236, PubMed 17562668
Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials
Expert Rev Cardiovasc Ther, 5 (3), 451-61
DOI 10.1586/14779072.5.3.451, PubMed 17489670
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension
Blood Press, 16 (2), 72-9
DOI 10.1080/08037050701338985, PubMed 17612904
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
J Hypertens, 25 (1), 15-23
DOI 10.1097/01.hjh.0000254378.26607.1f, PubMed 17143167
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke
Vasc Health Risk Manag, 3 (3), 299-305
PubMed 17703637
Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy
J Clin Hypertens (Greenwich), 8 (7), 487-92
DOI 10.1111/j.1524-6175.2006.05366.x, PubMed 16849902
Treatment of isolated systolic hypertension in diabetes mellitus type 2
Diabetes Obes Metab, 8 (4), 381-7
DOI 10.1111/j.1463-1326.2005.00523.x, PubMed 16776744
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials
Expert Opin Pharmacother, 7 (5), 575-81
DOI 10.1517/14656566.7.5.575, PubMed 16553573
Treatment of Hypertension in patients with type-2 diabetes mellitus
Blood Press, 15 (1), 62-3
DOI 10.1080/080370505100088999, PubMed 16566081
The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?
Am J Cardiovasc Drugs, 6 (3), 139-47
DOI 10.2165/00129784-200606030-00001, PubMed 16780387
Treatment of hypertension in patients with congestive cardiac failure
Heart Fail Monit, 5 (2), 38-43
PubMed 16816875
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Expert Opin Emerg Drugs, 10 (4), 729-45
DOI 10.1517/14728214.10.4.729, PubMed 16262560
Antihypertensive treatment and new-onset diabetes mellitus
Curr Hypertens Rep, 7 (4), 298-303
DOI 10.1007/s11906-005-0029-9, PubMed 16061050
[Uric acid--more deleterious than we thought?]
Tidsskr Nor Laegeforen, 125 (10), 1330-2
PubMed 15909004
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide
Am J Cardiovasc Drugs, 5 (1), 17-22
DOI 10.2165/00129784-200505010-00003, PubMed 15631534
[Hypertension and heart disease]
Tidsskr Nor Laegeforen, 124 (6), 802-5
PubMed 15039815
Never mind the quality, feel the width--ALLHAT revisited
Blood Press, 13 (6), 330-4
DOI 10.1080/08037050410004576, PubMed 15771216
2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension
J. Hypertens., 21 (6), 1011-1053
DOI 10.1097/01.hjh.0000059051.65882.32
Hypertension treatment and stroke prevention
Blood Press, 12 (5-6), 264-8
DOI 10.1080/08037050310016501, PubMed 14763656
[Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents]
Ugeskr Laeger, 164 (1), 18-21
PubMed 11810791
Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials
Blood Press, 10 (4), 190-2
DOI 10.1080/08037050152669684, PubMed 11800055
Home blood pressure monitoring. Current knowledge and directions for future research
Blood Press, 10 (5-6), 271-87
DOI 10.1080/080370501753400584, PubMed 11822532
Evidence for mediating econeurocardiologic mechanisms
Occup Med, 15 (1), 117-62
PubMed 10620789
[An overview of hypertension studies with calcium antagonists]
Tidsskr Nor Laegeforen, 119 (13), 1878-82
PubMed 10382332
[Sudden cardiac death in hypertension]
Tidsskr Nor Laegeforen, 117 (16), 2337-40
PubMed 9265281
Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases
Blood Press, 5 (5), 260-3
DOI 10.3109/08037059609078057, PubMed 8879597
[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist]
Tidsskr Nor Laegeforen, 116 (4), 504-7
PubMed 8644056
Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment
Blood Press, 5 (1), 5-15
DOI 10.3109/08037059609062101, PubMed 8777473
[How to combine antihypertensive drugs?]
Tidsskr Nor Laegeforen, 115 (18), 2257-9
PubMed 7652723
[Refractory hypertension]
Tidsskr Nor Laegeforen, 115 (6), 723-4
PubMed 7900136
Hypertension therapy and risk of coronary heart disease: how do antihypertensives affect metabolic factors?
Cardiology, 86 (2), 89-93
DOI 10.1159/000176845, PubMed 7728812
[Antihypertensive treatment and risk of coronary disease. How significant is the antihypertensive effect for metabolic factors?]
Tidsskr Nor Laegeforen, 114 (4), 462-4
PubMed 8009486
[Can treatment of hypertension prevent myocardial infarction? New controlled clinical trials are proposed]
Tidsskr Nor Laegeforen, 113 (6), 737-40
PubMed 8096658
[Treatment of hypertension in the elderly]
Tidsskr Nor Laegeforen, 112 (17), 2221-4
PubMed 1523663
The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension
J Cardiovasc Pharmacol, 20 Suppl 8, S32-9
PubMed 1283768
The hypertension-coronary heart disease dilemma: the catecholamine-blood platelet connection
J Hypertens, 7 (11), 851-60
DOI 10.1097/00004872-198911000-00001, PubMed 2691575
Other articles
Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?
Blood Press, 33 (1), 2329571
DOI 10.1080/08037051.2024.2329571, PubMed 38555859
Rationale of treatment recommendations in the 2023 ESH hypertension guidelines
Eur J Intern Med, 121, 4-8
DOI 10.1016/j.ejim.2023.12.015, PubMed 38216445
The role of β-blockers in medical treatment
Curr Med Res Opin, 40 (sup1), 1-2
DOI 10.1080/03007995.2024.2324138, PubMed 38597062
TIME to face the reality about evening dosing of antihypertensive drugs in hypertension
Blood Press, 32 (1), 1-3
DOI 10.1080/08037051.2022.2142512, PubMed 36369908
Women's health, cardiovascular risk and hypertension: the perspective still needs to improve
Blood Press, 32 (1), 2193648
DOI 10.1080/08037051.2023.2193648, PubMed 37066492
Real-world data show the effect of statins in primary prevention
Eur J Prev Cardiol, 30 (17), 1881-1882
DOI 10.1093/eurjpc/zwad231, PubMed 37439146
Randomized Clinical Outcome Trials in Hypertension
Hypertension, 81 (1), 17-23
DOI 10.1161/HYPERTENSIONAHA.123.21725, PubMed 37795644
[Not Available]
Tidsskr Nor Laegeforen, 143 (12)
DOI 10.4045/tidsskr.22.0822, PubMed 37668137
Uric acid and left ventricular mass in prediction of cardiovascular risk-New insight from the URRAH study
Eur J Intern Med, 114, 45-46
DOI 10.1016/j.ejim.2023.05.016, PubMed 37179137
Key questions regarding the SYMPLICITY HTN-3 trial
Lancet, 401 (10385), 1336-1337
DOI 10.1016/S0140-6736(23)00340-9, PubMed 37087164
Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions
Blood Press, 31 (1), 164-168
DOI 10.1080/08037051.2022.2095254, PubMed 35876172
Hypertension management during the COVID-19 pandemic: what can we learn for the future?
Blood Press, 31 (1), 47-49
DOI 10.1080/08037051.2022.2058909, PubMed 35426323
Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure
Blood Press, 31 (1), 207-209
DOI 10.1080/08037051.2022.2107483, PubMed 35941816
Thirty years with LIFE-a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy
Blood Press, 31 (1), 125-128
DOI 10.1080/08037051.2022.2083578, PubMed 35674494
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes
Lancet Diabetes Endocrinol, 10 (12), 840
DOI 10.1016/S2213-8587(22)00312-6, PubMed 36427519
Blood pressure during moderate or maximal exercise: hardly two sides of the same coin
J Hypertens, 40 (6), 1243-1244
DOI 10.1097/HJH.0000000000003121, PubMed 35703887
A 30th anniversary and a glimpse of the future
Blood Press, 31 (1), 1-3
DOI 10.1080/08037051.2021.2021638, PubMed 35060412
Why we do not need a single independent international hypertension clinical practice guideline
J Hypertens, 39 (11), 2125-2127
DOI 10.1097/HJH.0000000000002940, PubMed 34224539
The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
Blood Press, 30 (6), 327-331
DOI 10.1080/08037051.2021.1995975, PubMed 34714185
Attended vs. unattended blood pressure - learnings beyond SPRINT
Blood Press, 30 (6), 439-440
DOI 10.1080/08037051.2021.1995981, PubMed 34714207
Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
Blood Press, 30 (5), 267-268
DOI 10.1080/08037051.2021.1975878, PubMed 34586009
Cuff-less measurements of blood pressure: are we ready for a change?
Blood Press, 30 (4), 205-207
DOI 10.1080/08037051.2021.1956178, PubMed 34308727
Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective
Hypertension, 78 (2), 555-558
DOI 10.1161/HYPERTENSIONAHA.121.17356, PubMed 34232677
Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes - from single pill combinations to monitoring of a nationwide health insurance database
Blood Press, 30 (3), 143-144
DOI 10.1080/08037051.2021.1917192, PubMed 33910432
In Memoriam: Jiří Widimský Sr. 1925-2020
J Hypertens, 39 (2), 386-388
DOI 10.1097/HJH.0000000000002768, PubMed 37696754
Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
Blood Press, 30 (1), 1-3
DOI 10.1080/08037051.2021.1862483, PubMed 33349063
In memoriam: Jiří Widimský Sr. 1925-2020
Blood Press, 30 (2), 140-142
DOI 10.1080/08037051.2020.1859212, PubMed 33342305
In memoriam: Peter Sleight 1929-2020
J. Hypertens., 38 (12), 2546-2548
DOI 10.1097/HJH.0000000000002713
In memoriam: Peter Sleight 1929-2020
Blood Press, 29 (6), 382-384
DOI 10.1080/08037051.2020.1839224, PubMed 33153320
Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
Blood Press, 29 (6), 341-343
DOI 10.1080/08037051.2020.1838766, PubMed 33140684
Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime
J Hypertens, 38 (11), 2144-2145
DOI 10.1097/HJH.0000000000002671, PubMed 33027108
The International Society of Hypertension Guidelines 2020 - a new drug treatment recommendation in the wrong direction?
Blood Press, 29 (5), 264-266
DOI 10.1080/08037051.2020.1806494, PubMed 32808555
Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project
J Hypertens (in press) (Retracted)
DOI 10.1097/HJH.0000000000002479, PubMed 32516290
Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
Blood Press, 29 (4), 199-201
DOI 10.1080/08037051.2020.1782595, PubMed 32584173
In memoriam Eivind Berge, MD, PhD, 1964-2020: cardiologist, trialist and hypertension/stroke researcher
J. Hypertens., 38 (6), 1199-1200
DOI 10.1097/HJH.0000000000002488
Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project
Blood Press, 29 (3), 135-136
DOI 10.1080/08037051.2020.1747696, PubMed 32338542
Poor reproducibility of masked and white coat uncontrolled hypertension: important new information on MUCH and WUCH
Eur Heart J, 41 (16), 1572-1574
DOI 10.1093/eurheartj/ehz703, PubMed 31580419
Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke
Stroke, 51 (5), 1353-1355
DOI 10.1161/STROKEAHA.120.029351, PubMed 32200755
How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
Blood Press, 29 (2), 68-69
DOI 10.1080/08037051.2020.1726101, PubMed 32049554
Assessing hypertension therapies: randomization or confounding by indication?
Nat Rev Cardiol, 17 (2), 73-74
DOI 10.1038/s41569-019-0313-z, PubMed 31768007
The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
Blood Press, 29 (1), 1-2
DOI 10.1080/08037051.2020.1707440, PubMed 31902246
Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes
Blood Press, 28 (6), 356-357
DOI 10.1080/08037051.2019.1678261, PubMed 31623467
The PARAGON-Heart failure trial - another disappointment for heart failure patients with hypertension and preserved ejection fraction
Blood Press, 28 (5), 276-278
DOI 10.1080/08037051.2019.1664717, PubMed 31542958
Are People With Masked Hypertension Adherent to Their Antihypertensive Medication?
Hypertension, 74 (3), 497-498
DOI 10.1161/HYPERTENSIONAHA.119.13350, PubMed 31327260
The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
Blood Press, 28 (4), 215-216
DOI 10.1080/08037051.2019.1625523, PubMed 31184508
Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
Blood Press, 28 (3), 144-145
DOI 10.1080/08037051.2019.1614278, PubMed 31076016
Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines for Norway
Eur Heart J, 40 (19), 1485-1487
DOI 10.1093/eurheartj/ehz266, PubMed 31087051
Could adverse events offset the benefit of intensive blood pressure lowering treatment in the Systolic Blood Pressure Intervention Trial?
J Hypertens, 37 (5), 902-904
DOI 10.1097/HJH.0000000000002018, PubMed 30920495
Future of Renal Sympathetic Denervation in the Treatment of Hypertension
J Am Coll Cardiol, 73 (13), 1643-1645
DOI 10.1016/j.jacc.2019.02.008, PubMed 30947916
Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy
Eur Heart J Cardiovasc Pharmacother, 5 (2), 122-123
DOI 10.1093/ehjcvp/pvz005, PubMed 30698668
Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
Blood Press, 28 (2), 75-76
DOI 10.1080/08037051.2019.1584975, PubMed 30806086
New data on antihypertensive drugs and risk of cancer: should we worry?
Blood Press, 28 (1), 1-3
DOI 10.1080/08037051.2019.1568182, PubMed 30714837
Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk: implications for understanding the SPRINT results
J Hypertens, 37 (1), 6-8
DOI 10.1097/HJH.0000000000001874, PubMed 30499916
Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues
Eur Heart J, 39 (47), 4221
DOI 10.1093/eurheartj/ehy605, PubMed 30496492
2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension
Blood Press, 27 (6), 313
DOI 10.1080/08037051.2018.1530564, PubMed 30380927
Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study
Blood Press, 27 (5), 247-248
DOI 10.1080/08037051.2018.1507621, PubMed 30175661
Take a Blood Pressure Pill or Benefit from Renal Denervation?
Eur Heart J, 39 (33), 3010-3012
DOI 10.1093/eurheartj/ehy440, PubMed 30990870
Optimal Blood Pressure Target in Diabetic and Nondiabetic Hypertensive Patients
Circ Res, 123 (5), 528-530
DOI 10.1161/CIRCRESAHA.118.312763, PubMed 30355140
Final Farewell to Alber to Zanchetti MD
Eur. Heart J., 39 (28), 2616-2617
DOI 10.1093/eurheartj/ehy327
Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mm Hg in Patients With Diabetes Mellitus Participating in ACCORD?
Hypertension, 72 (2), 291-293
DOI 10.1161/HYPERTENSIONAHA.118.11455, PubMed 29967041
Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure
Blood Press, 27 (4), 185-187
DOI 10.1080/08037051.2018.1486178, PubMed 29936868
Take a blood pressure pill or undergo renal denervation?
Lancet, 391 (10137), 2298-2300
DOI 10.1016/S0140-6736(18)31126-7, PubMed 29803587
New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?
Blood Press, 27 (2), 62-65
DOI 10.1080/08037051.2018.1430504, PubMed 29447001
In memoriam: Alberto Zanchetti
Blood Pressure, 27 (3), 123-124
DOI 10.1080/08037051.2018.1464383
European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2016; 17: Nr. 63* Treatment of High Blood Pressure in Elderly and Octogenarians
J. Hyperton., 22 (2), 46-48
Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions
Blood Press, 27 (1), 1-2
DOI 10.1080/08037051.2017.1407218, PubMed 29179586
Reply
J Hypertens, 35 (11), 2327-2328
DOI 10.1097/HJH.0000000000001526, PubMed 28953595
Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?
Blood Press, 26 (6), 319-320
DOI 10.1080/08037051.2017.1386539, PubMed 28975817
Consensus document on hypertension and cardiac arrhythmias
Eur Heart J Cardiovasc Pharmacother, 3 (4), 251-252
DOI 10.1093/ehjcvp/pvx022, PubMed 28922836
Expertise: no longer a sine qua non for guideline authors?
J Hypertens, 35 (8), 1564-1566
DOI 10.1097/HJH.0000000000001435, PubMed 28657972
Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?
Blood Press, 26 (4), 193-194
DOI 10.1080/08037051.2017.1332478, PubMed 28566004
Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials
Blood Press, 26 (5), 257-258
DOI 10.1080/08037051.2017.1357110, PubMed 28724313
Expertise: No Longer a Sine Qua Non for Guideline Authors?
Hypertension, 70 (2), 235-237
DOI 10.1161/HYPERTENSIONAHA.117.09470, PubMed 28652465
Interventions to improve adherence of antihypertensive medication in African-Americans
J Hypertens, 35 (6), 1164-1165
DOI 10.1097/HJH.0000000000001249, PubMed 28441256
Adopting Systolic Pressure Intervention Trial (SPRINT)-like office blood pressure measurements in clinical practice
J Hypertens, 35 (3), 471-472
DOI 10.1097/HJH.0000000000001229, PubMed 28121838
The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke
Blood Press, 26 (3), 131-132
DOI 10.1080/08037051.2017.1292456, PubMed 28224820
Letter by Messerli et al Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure"
Circulation, 135 (7), e45-e46
DOI 10.1161/CIRCULATIONAHA.116.025301, PubMed 28193803
Blood pressure goals in type 2 diabetes-assessing the evidence
Lancet Diabetes Endocrinol, 5 (5), 319-321
DOI 10.1016/S2213-8587(17)30035-9, PubMed 28169174
The INTERSALT Study and the complex relationship between salt intake and blood pressure
Blood Press, 26 (2), 65-66
DOI 10.1080/08037051.2016.1274957, PubMed 28049345
The Global Burden of Disease Study 2015 and Blood Pressure
Blood Press, 26 (1), 1
DOI 10.1080/08037051.2016.1267557, PubMed 27951726
Blood Pressure in 2016: increased impact factor and change of editors
Blood Press, 25 (6), 331-332
DOI 10.1080/08037051.2016.1225493, PubMed 27592522
Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials
J Hypertens, 34 (8), 1489-91
DOI 10.1097/HJH.0000000000001002, PubMed 27355995
Arterial Stiffness Predicts Incident Atrial Fibrillation in the Framingham Heart Study: A Mechanistic Contribution in People With High Blood Pressure or History of Hypertension
Hypertension, 68 (3), 555-7
DOI 10.1161/HYPERTENSIONAHA.116.07671, PubMed 27456524
HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg
Blood Press, 25 (3), 131-2
DOI 10.1080/08037051.2016.1182857, PubMed 27160151
High blood pressure in US diabetic veterans with normal renal function: a plea for the design of a more powerful and conclusive outcome trial
J Hypertens, 34 (5), 836-7
DOI 10.1097/HJH.0000000000000896, PubMed 27027378
The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease
Blood Press, 25 (5), 276-9
DOI 10.3109/08037051.2016.1139324, PubMed 27071504
Hypertension: When should we treat hypertension in patients with diabetes?
Nat Rev Cardiol, 13 (5), 252-3
DOI 10.1038/nrcardio.2016.49, PubMed 27053453
[Limited basis for changing the goals for blood pressure treatment]
Tidsskr Nor Laegeforen, 136 (3), 209-10
DOI 10.4045/tidsskr.15.1298, PubMed 26860378
Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg
Eur Heart J Cardiovasc Pharmacother, 2 (2), 79-80
DOI 10.1093/ehjcvp/pvw002, PubMed 27533517
The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg
Blood Press, 25 (2), 63-6
DOI 10.3109/08037051.2015.1130775, PubMed 26743157
Peter Meredith
Blood Press, 25 (2), 129-30
DOI 10.3109/08037051.2016.1139360, PubMed 26873622
The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg
Blood Press, 25 (1), 1-3
DOI 10.3109/08037051.2016.1096564, PubMed 26462684
Blood pressure and early neurological deterioration in acute ischemic stroke
J Hypertens, 33 (10), 2020-1
DOI 10.1097/HJH.0000000000000689, PubMed 26431189
The setback of renal denervation should not backfire on sympathetic overactivity in hypertension
J Am Coll Cardiol, 65 (13), 1322-1323
DOI 10.1016/j.jacc.2015.01.038, PubMed 25835444
Design of renal denervation studies not confounded by antihypertensive drugs
J Am Soc Hypertens, 9 (5), 337-40
DOI 10.1016/j.jash.2015.02.015, PubMed 25863572
Cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension and improving patients' adherence
J Hypertens, 32 (12), 2357-8
DOI 10.1097/HJH.0000000000000385, PubMed 25376250
[Re: Renal sympathetic denervation in treatment-resistant hypertension]
Tidsskr Nor Laegeforen, 134 (15), 1449-50
DOI 10.4045/tidsskr.14.0931, PubMed 25138398
Ingrid Toft (June 2, 1959-April 26, 2014)
Blood Press, 23 (4), 255
DOI 10.3109/08037051.2014.938919, PubMed 25014276
Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials
Blood Press, 23 (3), 135-7
DOI 10.3109/08037051.2014.916896, PubMed 24842262
Hypertension management by practice guidelines
Blood Press, 23 (1), 1-2
DOI 10.3109/08037051.2014.881646, PubMed 24548004
Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al
Circ Arrhythm Electrophysiol, 6 (6), e102
DOI 10.1161/CIRCEP.113.001154, PubMed 24347602
[Blood Pressure Treatment--towards consensus on many things]
Tidsskr Nor Laegeforen, 133 (21), 2226
DOI 10.4045/tidsskr.13.1374, PubMed 24226313
Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3
Blood Press, 22 (5), 279-81
DOI 10.3109/08037051.2013.840445, PubMed 24059787
First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern
J Am Coll Cardiol, 62 (21), e445-e446
DOI 10.1016/j.jacc.2013.07.095, PubMed 24060455
No support for renal denervation in a meta-analysis
J Am Coll Cardiol, 62 (21), 2029-2030
DOI 10.1016/j.jacc.2013.07.094, PubMed 24060456
Combination treatment in hypertension - the latest 2013 European Guidelines
Blood Press, 22 Suppl 1, 1-2
DOI 10.3109/08037051.2013.826471, PubMed 23978052
2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines
Blood Press, 22 (4), 191-2
DOI 10.3109/08037051.2013.817814, PubMed 23855424
Authors' reply to the letter from Dr Wang: troponins after coronary artery bypass grafting: continuous or cut-point approach?
Am Heart J, 166 (2), e3
DOI 10.1016/j.ahj.2013.05.001, PubMed 23895825
Primary cardiovascular prevention by Mediterranean diet - the PREDIMED trial
Blood Press, 22 (3), 129-30
DOI 10.3109/08037051.2013.793882, PubMed 23659248
Revisiting the pre-hypertension debate: increasing evidence for treatment--or not?
Blood Press, 22 (6), 344
DOI 10.3109/08037051.2013.787711, PubMed 23635037
Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects
EuroIntervention, 9 Suppl R, R7-9
DOI 10.4244/EIJV9SRA1, PubMed 23732159
Wolfgang Kiowski 1949-2012 In Memoriam
Hypertension, 61 (2), 268-269
DOI 10.1161/HYPERTENSIONAHA.111.00619
Catheter-based renal denervation: a word of caution
EuroIntervention, 8 (9)
DOI 10.4244/EIJV8I9A152, PubMed 23339819
Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure
Blood Press, 21 (6), 329-30
DOI 10.3109/10582452.2012.741765, PubMed 23210746
Direct renin inhibitors in hypertension - approaching the moment of truth
Blood Press, 21 (5), 267-8
DOI 10.3109/08037051.2012.728304, PubMed 23013445
High resting heart rate predicts mortality, disability, and cognitive decline in patients after ischaemic stroke: time for additional selective I(f) channel inhibitor trials?
Eur Heart J, 33 (22), 2761-3
DOI 10.1093/eurheartj/ehs260, PubMed 22922504
State of global health--hypertension burden and control
Blood Press, 21 Suppl 1, 1-2
DOI 10.3109/08037051.2012.704786, PubMed 22809199
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension
J Hypertens, 30 (5), 887-9
DOI 10.1097/HJH.0b013e328352c507, PubMed 22495133
Increased time varying heart rate and cardiovascular risk in hypertension: benefit of selective I((f)) channel inhibitor?
Blood Press, 21 (1), 1-2
DOI 10.3109/08037051.2012.652818, PubMed 22263600
Post-registration studies for the evaluation of antihypertensive drugs
Blood Press Suppl, 2, 3-4
DOI 10.3109/08037051.2011.631283, PubMed 22352119
An appropriate SCORE to assess cardiovascular risk in hypertension?
Blood Press, 20 (6), 320-1
DOI 10.3109/08037051.2011.625628, PubMed 22077635
Bjarne Magnus Iversen (30 March 1942-5 August 2011) OBITUARY
Blood Pressure, 20 (5), 317
DOI 10.3109/08037051.2011.617859
Renal nerve ablation: emerging role in therapeutics
Blood Press, 20 (5), 253-5
DOI 10.3109/08037051.2011.613296, PubMed 21905971
High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts: a plea for early drug treatment?
Blood Press, 20 (4), 188-9
DOI 10.3109/08037051.2011.595962, PubMed 21780952
Antihypertensive therapy and cancer risks?
Blood Press, 20 (3), 127-8
DOI 10.3109/08037051.2011.575554, PubMed 21599451
Spotlight: Sverre Erik Kjeldsen, MD, PhD, FAHA, FESC
Circulation, 123 (16), F91-F95
Treatment of high blood pressure in acute stroke--the SCAST study
Blood Press, 20 (2), 67-8
DOI 10.3109/08037051.2011.564914, PubMed 21405956
Controversies in hypertension treatment
Curr Vasc Pharmacol, 8 (6), 731-2
DOI 10.2174/157016110793563915, PubMed 20840062
Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports
Blood Press, 19 (5), 271-2
DOI 10.3109/08037051.2010.518666, PubMed 20858047
Angiotensin-receptor blockade, cancer, and concerns
Lancet Oncol, 11 (9), 820-1; author reply 821-2
DOI 10.1016/S1470-2045(10)70159-5, PubMed 20816379
Blood pressure variability: Emerging role in risk assessment and therapeutics
Blood Press, 19 (4), 209-11
DOI 10.3109/08037051.2010.510279, PubMed 20684659
Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire
J Hypertens, 28 (7), 1593-4
DOI 10.1097/HJH.0b013e32833b7b08, PubMed 20574253
Blood Pressure celebrates 20 years of dedication to Nordic hypertension research
Blood Press, 19 (3), 130-1
DOI 10.3109/08037051.2010.487989, PubMed 20482441
Blood pressure and migration
Blood Press, 19 (2), 65-6
DOI 10.3109/08037051003731724, PubMed 20367544
Hypertension research into the new millennium
Blood Press, 19 (1), 1-2
DOI 10.3109/08037051003650874, PubMed 20175651
Implementation of 24-hour blood pressure control
Blood Press Suppl, 1, 3-4
DOI 10.3109/08037051003668884, PubMed 20175713
Critical aspects in hypertension diagnosis and treatment
Blood Press Suppl, 1, 3-4
PubMed 20050099
[Solid guidelines for prevention of cardiovascular diseases]
Tidsskr Nor Laegeforen, 129 (16), 1660
DOI 10.4045/tidsskr.09.0851, PubMed 19721488
Should we treat prehypertension?
Blood Press, 18 (6), 298-9
DOI 10.3109/08037050903416410, PubMed 20001652
The surge of Japanese studies supporting the use of angiotensin receptor blockers in hypertension
Blood Press, 18 (5), 240-1
DOI 10.3109/08037050903318769, PubMed 19919393
Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?
Blood Press, 18 (3), 92-3
DOI 10.1080/08037050903040777, PubMed 19484619
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Blood Press, 18 (1-2), 4-6
DOI 10.1080/08037050902742282, PubMed 19191085
The J-curve phenomenon revisited
Blood Press, 18 (4), 168-70
DOI 10.1080/08037050903145386, PubMed 20804362
More focus on therapeutic targets and improved tolerability in hypertension
Blood Press Suppl, 2, 3-4
DOI 10.1080/08038020802571775, PubMed 19203018
Achieving better blood pressure control
Blood Press Suppl, 1, 3-4
DOI 10.1080/08038020802184504, PubMed 18705529
European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces
J Hypertens, 26 (2), 157-60
DOI 10.1097/HJH.0b013e3282f424f9, PubMed 18192823
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET
Blood Press, 17 (2), 68-9
DOI 10.1080/08037050802117791, PubMed 18568694
Benefits of hypertension management in diabetes: an opportunity not to be missed
Blood Press, 17 (5-6), 248-9
DOI 10.1080/08037050802636105, PubMed 19085534
Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment
Blood Press, 17 (1), 5-6
DOI 10.1080/08037050801972949, PubMed 18568686
More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension
Blood Press, 17 (3), 132-3
DOI 10.1080/08037050802312418, PubMed 18665471
Management of older hypertensive patients
Blood Press, 17 (4), 184-5
DOI 10.1080/08037050802486642, PubMed 18932064
ESH hypertension excellence centres: a new strategy to combat an old foe
J. Hypertens., 25 (8), 1744-1748
DOI 10.1097/HJH.0b013e328286266e
There is a need for more aggressive implementation of combination strategies to control hypertensive risk
Blood Press Suppl, 1, 4-5
DOI 10.1080/08038020701244037, PubMed 17566312
Blood pressure control--slowly getting there through new strategies?
Blood Press, 16 (2), 68-71
DOI 10.1080/08037050701428174, PubMed 17612903
New ESH/ESC guidelines signal progress in hypertension management
Blood Press, 16 (3), 132-4
DOI 10.1080/08037050701550746, PubMed 17846924
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy
Blood Press, 16 (6), 344-6
DOI 10.1080/08037050701797263, PubMed 18058453
Hypertension and cardiovascular disease: is arterial stiffness the heart of the matter?
Blood Press, 16 (4), 236-7
DOI 10.1080/08037050701645033, PubMed 17917863
Documentation of endpoint prevention with combination therapy in hypertension is urgently needed
Blood Press, 16 (1), 4-5
DOI 10.1080/08037050701342599, PubMed 17453745
European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs
J Hypertens, 24 (12), 2478-82
DOI 10.1097/HJH.0b013e328010b96f, PubMed 17082736
RAAS inhibition--a practice of medical progress
Blood Press Suppl, 1, 5-6
DOI 10.1080/08038020600613480, PubMed 16513578
Cost-effectiveness of blood pressure measurement and hypertension follow-up
Blood Press, 15 (1), 4-5
DOI 10.1080/08037050600587591, PubMed 16492609
Medical decision making in hypertension
Blood Press, 15 (4), 196-7
DOI 10.1080/08037050601002822, PubMed 17060114
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
Blood Press, 15 (5), 260-2
DOI 10.1080/08037050601121804, PubMed 17380842
An American TROPHY in the prevention of hypertension
Blood Press, 15 (3), 132-4
DOI 10.1080/08037050600819739, PubMed 16864154
ESH statement on detection and punishment of abstract fraud and poster plagiarism
J Hypertens, 24 (1), 203-4
DOI 10.1097/01.hjh.0000198043.31881.11, PubMed 16331121
Hypertension and cardiovascular disease in women: progress towards better understanding of gender-specific differences?
Blood Press, 15 (2), 68-70
DOI 10.1080/08037050600750165, PubMed 16754268
Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus
J Hypertens, 24 (1), 208-10
DOI 10.1097/01.hjh.0000198038.01387.9b, PubMed 16331123
Prevention of type 2 diabetes mellitus with antihypertensive drugs
Blood Press, 15 (4), 253-4
PubMed 17078188
Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?
Blood Press, 15 (6), 323-4
DOI 10.1080/08037050601164986, PubMed 17472021
More heat to support aggressive blood pressure lowering: the FEVER study
J Hypertens, 23 (12), 2145-6
DOI 10.1097/01.hjh.0000194123.27475.25, PubMed 16269953
Hypertension control- A global challenge
Blood Press Suppl, 1, 4-5
DOI 10.1080/08037050510034266, PubMed 16144128
Home blood pressure monitoring
J Hypertens, 23 (7), 1437-9
DOI 10.1097/01.hjh.0000173532.03674.5a, PubMed 15942472
Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE
Curr Hypertens Rep, 7 (3), 155-7
DOI 10.1007/s11906-005-0001-8, PubMed 15913486
Health economy of the metabolic syndrome pandemic
Blood Press, 14 (3), 131-2
DOI 10.1080/08037051510034310, PubMed 16036491
Hypertension and coronary artery disease: mechanistic insights and therapeutic challenges
Blood Press, 14 (5), 260-1
DOI 10.1080/08037050500350876, PubMed 16257869
Angiotensin receptor blockers and endpoint protection
Blood Press, 14 (4), 195
DOI 10.1080/08037050500224006, PubMed 16126552
ESH statement on detection and punishment of abstract fraud and poster plagiarism
Blood Press, 14 (6), 322-3
DOI 10.1080/08037050500445619, PubMed 16403685
Is smoking a causative factor of hypertension?
Blood Press, 14 (2), 69-71
DOI 10.1080/08037050510034202, PubMed 16036482
Renal hypertensive target organ damage--new evidence emerges in diabetics and smokers
Blood Press, 13 (6), 324-5
DOI 10.1080/08037050410010416, PubMed 15771214
Valuable lessons from VALUE
Blood Press, 13 (4), 196-7
DOI 10.1080/080370504100000912, PubMed 15581332
Cardiovascular risk stratification: an important tool for treatment to lower cardiovascular disease risk
Blood Press, 13 (3), 125-6
DOI 10.1080/08037050410015088, PubMed 15223719
Hypertension in very old people
J Hypertens, 21 (12), 2249-50
DOI 10.1097/00004872-200312000-00011, PubMed 14654743
Comparison of the SCOPE and LIFE results
J Hypertens, 21 (9), 1772-3; author reply 1773
DOI 10.1097/00004872-200309000-00030, PubMed 12923412
Novel aspects of therapeutics in Blood Pressure: drug therapy supplements
Blood Press Suppl, 1, 4
DOI 10.1080/08038020310000131, PubMed 21067342
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
Blood Press, 12 (3), 132-3
DOI 10.1080/08037050310008005, PubMed 12875472
Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC
Blood Press, 12 (4), 196-7
DOI 10.1080/08037050310015854, PubMed 14596354
Contrasting messages but not contradicting results from ALLHAT and ANBP2
Blood Press, 12 (2), 68-9
DOI 10.1080/08037050310004658, PubMed 12797626
Masked hypertension--a new entity and challenge for clinical hypertension research and management
Blood Press, 12 (5-6), 261-3
DOI 10.1080/08037050310025178, PubMed 14763655
Warning for antihypertensive drug?
Lancet, 358 (9288), 1181-2
DOI 10.1016/s0140-6736(01)06280-8, PubMed 11597701
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study
Lancet, 356 (9245), 1929-30
DOI 10.1016/s0140-6736(05)73480-2, PubMed 11130406
Bicycle exercise blood pressure can be useful in a clinical practice
J Hypertens, 17 (1), 147-8
DOI 10.1097/00004872-199917010-00022, PubMed 10100107
Preeclampsia - a state of sympathetic overactivity
N Engl J Med, 336 (18), 1326-7; author reply 1327
PubMed 9132597
[The Norwegian Society for Stroke]
Tidsskr Nor Laegeforen, 115 (13), 1659
PubMed 7778086
[Is blood pressure treatment as effective in the population as in controlled trials?]
Tidsskr Nor Laegeforen, 115 (1), 102-3
PubMed 7846647
[Is blood pressure therapy as effective in the general population as in controlled trials?]
Tidsskr Nor Laegeforen, 114 (28), 3359-60
PubMed 7809899
[What do we know about "white coat" hypertension?]
Nord Med, 108 (5), 135
PubMed 8497401
[Treatment of hypertension in Norway. Indications, therapeutic intensity and economic aspects]
Tidsskr Nor Laegeforen, 112 (1), 69-70
PubMed 1553650
Increased erythrocyte magnesium in never treated essential hypertension
Am J Hypertens, 3 (7), 573-5
DOI 10.1093/ajh/3.7.573, PubMed 2194511
Long-term pacing in VVI-modes elicit similar sympathetic drive
Pacing Clin Electrophysiol, 11 (7), 1114-5
DOI 10.1111/j.1540-8159.1988.tb03960.x, PubMed 2457893
Increase in beta-thromboglobulin during exercise
Thromb Res, 48 (1), 111-5
DOI 10.1016/0049-3848(87)90351-3, PubMed 2962334
Does arterial rather than venous plasma beta-thromboglobulin better reflect in vivo platelet release reaction?
Thromb Haemost, 54 (2), 547
PubMed 2417355
Arterial plasma adrenaline in essential hypertension
Scand J Clin Lab Invest, 44 (4), 271-4
DOI 10.3109/00365518409083807, PubMed 6463559
Books
Sykdomslære: indremedisin, kirurgi og anestesi
Gyldendal akademisk, Oslo, 703 s.
BIBSYS 000601713, ISBN 978-82-00-42441-3
Indremedisin og kirurgi
Universitetsforl., Oslo (4. utg.), 331 s.
BIBSYS 940316927, ISBN 82-00-40907-4
Spørsmål og svar om hypertensjon og ACE-hemmere
MSD, Drammen ([2. utg.]), 28 s.
BIBSYS 942714032
Indremedisin og kirurgi
Universitetsforl., Oslo (3. utg.), 300 s.
BIBSYS 890149275, ISBN 82-00-43076-6
Akutte forgiftninger: en veileder
Universitetsforlaget, Oslo (2. utg.), 204 s.
BIBSYS 885012542, ISBN 82-00-43046-4
Some aspects of the sympathetic nervous system with special reference to essential hypertension
[S. E. Kjeldsen], Oslo, 1 b.(flere pag.)
BIBSYS 842195734, ISBN 82-991115-0-1
Indremedisin og kirurgi 1
In Sykdomslære, Universitetsforlaget, Oslo, 1, 384 s.
BIBSYS 845005766, ISBN 82-00-28739-4
Medisinsk sykdomslære
Universitetsforl., Oslo, 338 s.
BIBSYS 822070855, ISBN 82-00-27774-7